Multiple	O
closely-linked	O
NFAT/octamer	B-DNA
and	O
HMG	B-DNA
I	I-DNA
(	I-DNA
Y	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
are	O
part	O
of	O
the	O
interleukin-4	O
promoter	O
.	O

We	O
show	O
here	O
that	O
the	O
immediate	B-DNA
upstream	I-DNA
region	I-DNA
(	O
from	O
position	O
-12	O
to	O
-270	O
)	O
of	O
the	O
murine	B-DNA
interleukin	I-DNA
4	I-DNA
(	I-DNA
Il-4	I-DNA
)	I-DNA
gene	I-DNA
harbors	O
a	O
strong	O
cell-type	O
specific	O
transcriptional	B-DNA
enhancer	I-DNA
.	O

In	O
T	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
,	O
the	O
activity	O
of	O
the	O
Il-4	B-DNA
promoter/enhancer	I-DNA
is	O
stimulated	O
by	O
phorbol	O
esters	O
,	O
Ca++	O
ionophores	O
and	O
agonists	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
and	O
inhibited	O
by	O
low	O
doses	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

The	O
Il-4	B-DNA
promoter/enhancer	I-DNA
is	O
transcriptionally	O
inactive	O
in	O
B	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_type
cells	I-cell_type
.	O

DNase	O
I	O
footprint	O
protection	O
experiments	O
revealed	O
six	O
sites	O
of	O
the	O
Il-4	B-DNA
promoter/enhancer	I-DNA
to	O
be	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O

Among	O
them	O
are	O
four	O
purine	O
boxes	O
which	O
have	O
been	O
described	O
to	O
be	O
important	O
sequence	O
motifs	O
of	O
the	O
Il-2	B-DNA
promoter	I-DNA
.	O

They	O
contain	O
the	O
motif	O
GGAAA	O
and	O
are	O
recognized	O
by	O
the	O
inducible	B-protein
and	I-protein
cyclosporin	I-protein
A-sensitive	I-protein
transcription	I-protein
factor	I-protein
NFAT-1	I-protein
.	O

Three	O
of	O
the	O
Il-4	B-DNA
NFAT-1	I-DNA
sites	I-DNA
are	O
closely	O
linked	O
to	O
weak	O
binding	O
sites	O
of	O
Octamer	B-protein
factors	I-protein
.	O

Several	O
purine	O
boxes	O
and	O
an	O
AT-rich	B-DNA
protein-binding	I-DNA
site	I-DNA
of	O
the	O
Il-4	O
promoter	O
are	O
also	O
recognized	O
by	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
HMG	B-protein
I	I-protein
(	I-protein
Y	I-protein
)	O
.	O

Whereas	O
the	O
binding	O
of	O
NFAT-1	B-protein
and	O
Octamer	B-protein
factors	I-protein
enhance	O
the	O
activity	O
of	O
the	O
Il-4	B-DNA
promoter	I-DNA
,	O
the	O
binding	O
of	O
HMG	O
I	O
(	O
Y	O
)	O
suppresses	O
its	O
activity	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
involved	O
in	O
the	O
suppression	O
of	O
Il-4	B-protein
transcription	O
in	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

5694-5704	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
Â©	NULL
1993	NULL
Oxford	NULL
University	NULL
Press	NULL
Multiple	NULL
closely-linked	NULL
NFAT/octamer	NULL
and	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
are	NULL
part	NULL
of	NULL
the	NULL
interleukin-4	NULL
promoter	NULL
Sergei	NULL
Chuvpilo+*	NULL
,	NULL
Christof	NULL
Schomberg	NULL
,	NULL
Rainer	NULL
Gerwig	NULL
'	NULL
,	NULL
Annette	NULL
Heinfling	NULL
,	NULL
Raymond	NULL
Reeves	NULL
,	NULL
Friedrich	NULL
Grummt	NULL
'	NULL
and	NULL
Edgar	NULL
Serfling*	NULL
Institute	NULL
of	NULL
Pathology	NULL
and	NULL
'Institute	NULL
of	NULL
Biochemistry	NULL
,	NULL
Biozentrum	NULL
,	NULL
Am	NULL
Hubland	NULL
,	NULL
University	NULL
of	NULL
Wurzburg	NULL
,	NULL
J.-Schneider-Str	NULL
.	NULL

7	NULL
,	NULL
D-97080	NULL
Wurzburg	NULL
,	NULL
Germany	NULL
and	NULL
*National	NULL
Institute	NULL
of	NULL
Child	NULL
Health	NULL
and	NULL
Human	NULL
Development	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
,	NULL
USA	NULL
Received	NULL
August	NULL
16	NULL
,	NULL
1993	NULL
;	NULL
Revised	NULL
and	NULL
Accepted	NULL
October	NULL
28	NULL
,	NULL
1993	NULL
ABSTRACT	NULL
We	NULL
show	NULL
here	NULL
that	NULL
the	NULL
immediate	NULL
upstream	NULL
region	NULL
(	NULL
from	NULL
position	NULL
-12	NULL
to	NULL
-	NULL
270	NULL
)	NULL
of	NULL
the	NULL
murine	NULL
Interleukin	NULL
4	NULL
(	NULL
I1-4	NULL
)	NULL
gene	NULL
harbors	NULL
a	NULL
strong	NULL
cell-type	NULL
specific	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

In	NULL
T	NULL
lymphoma	NULL
cells	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
is	NULL
stimulated	NULL
by	NULL
phorbol	NULL
esters	NULL
,	NULL
Ca++	NULL
ionophores	NULL
and	NULL
agonists	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
and	NULL
inhibited	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
the	NULL
immunosuppressant	NULL
cyclosporin	NULL
A	NULL
.	NULL

The	NULL
II-4	NULL
promoter/enhancer	NULL
is	NULL
transcriptionally	NULL
inactive	NULL
in	NULL
B	NULL
lymphoma	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

DNase	NULL
I	NULL
footprint	NULL
protection	NULL
experiments	NULL
revealed	NULL
six	NULL
sites	NULL
of	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
to	NULL
be	NULL
bound	NULL
by	NULL
nuclear	NULL
proteins	NULL
from	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cells	NULL
.	NULL

Among	NULL
them	NULL
are	NULL
four	NULL
purine	NULL
boxes	NULL
which	NULL
have	NULL
been	NULL
described	NULL
to	NULL
be	NULL
important	NULL
sequence	NULL
motifs	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
.	NULL

They	NULL
contain	NULL
the	NULL
motif	NULL
GGAAA	NULL
and	NULL
are	NULL
recognized	NULL
by	NULL
the	NULL
inducible	NULL
and	NULL
cyclosporin	NULL
A-sensitive	NULL
transcription	NULL
factor	NULL
NFAT-1	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
II-4	NULL
NFAT-1	NULL
sites	NULL
are	NULL
closely	NULL
linked	NULL
to	NULL
weak	NULL
binding	NULL
sites	NULL
of	NULL
Octamer	NULL
factors	NULL
.	NULL

Several	NULL
purine	NULL
boxes	NULL
and	NULL
an	NULL
AT-rich	NULL
protein-binding	NULL
site	NULL
of	NULL
the	NULL
11-4	NULL
promoter	NULL
are	NULL
also	NULL
recognized	NULL
by	NULL
the	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

Whereas	NULL
the	NULL
binding	NULL
of	NULL
NFAT-1	NULL
and	NULL
Octamer	NULL
factors	NULL
enhance	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
suppresses	NULL
its	NULL
activity	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
appears	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
suppression	NULL
of	NULL
I1-4	NULL
transcription	NULL
in	NULL
resting	NULL
T	NULL
lymphocytes	NULL
.	NULL

INTRODUCTION	NULL
Peripheral	NULL
CD4+8~	NULL
T	NULL
lymphocytes	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
differentiation	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
these	NULL
so-called	NULL
T	NULL
helper	NULL
(	NULL
Th	NULL
)	NULL
cells	NULL
are	NULL
in	NULL
a	NULL
resting	NULL
state	NULL
,	NULL
i.e	NULL
.	NULL

they	NULL
neither	NULL
secrete	NULL
cytokines	NULL
nor	NULL
do	NULL
they	NULL
proliferate	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
interaction	NULL
with	NULL
presented	NULL
antigens	NULL
and/or	NULL
other	NULL
inducers	NULL
,	NULL
Th	NULL
cells	NULL
synthesize	NULL
and	NULL
secrete	NULL
Interleukin	NULL
2	NULL
(	NULL
I-2	NULL
)	NULL
and	NULL
further	NULL
cytokines	NULL
.	NULL

According	NULL
to	NULL
the	NULL
patterns	NULL
of	NULL
secreted	NULL
cytokines	NULL
,	NULL
Th	NULL
cell	NULL
clones	NULL
have	NULL
been	NULL
classified	NULL
into	NULL
several	NULL
subtypes	NULL
.	NULL

Two	NULL
T	NULL
helper	NULL
subtypes	NULL
,	NULL
Thl	NULL
and	NULL
Th2	NULL
cells	NULL
,	NULL
have	NULL
been	NULL
described	NULL
in	NULL
the	NULL
mouse	NULL
.	NULL

Th1	NULL
and	NULL
Th2	NULL
cells	NULL
synthesize	NULL
distinct	NULL
sets	NULL
of	NULL
cytokines	NULL
.	NULL

Thi	NULL
cells	NULL
predominantly	NULL
synthesize	NULL
and	NULL
secrete	NULL
I1-2	NULL
,	NULL
Interferon-y	NULL
and	NULL
Lymphctoxin	NULL
and	NULL
are	NULL
responsible	NULL
for	NULL
delayed	NULL
type	NULL
hypersensitivity	NULL
functions	NULL
,	NULL
whereas	NULL
Th2	NULL
cells	NULL
synthesize	NULL
1-4	NULL
,	NULL
11-5	NULL
,	NULL
11-6	NULL
and	NULL
I-10	NULL
(	NULL
but	NULL
not	NULL
II-2	NULL
and	NULL
Interferon-y	NULL
)	NULL
and	NULL
are	NULL
more	NULL
efficient	NULL
helpers	NULL
for	NULL
antibody	NULL
production	NULL
(	NULL
see	NULL
1	NULL
for	NULL
a	NULL
review	NULL
)	NULL
.	NULL

Although	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
apparently	NULL
represent	NULL
the	NULL
endpoints	NULL
of	NULL
a	NULL
wide	NULL
spectrum	NULL
of	NULL
cytokine	NULL
patterns	NULL
,	NULL
there	NULL
are	NULL
in	NULL
vivo	NULL
situations	NULL
,	NULL
particularly	NULL
in	NULL
parasitic	NULL
infections	NULL
,	NULL
in	NULL
which	NULL
the	NULL
distinct	NULL
Th1	NULL
and	NULL
Th2	NULL
subtypes	NULL
contribute	NULL
in	NULL
a	NULL
large	NULL
extent	NULL
to	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
see	NULL
2	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
which	NULL
account	NULL
for	NULL
the	NULL
divergent	NULL
expression	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
different	NULL
subsets	NULL
of	NULL
T	NULL
lymphocytes	NULL
have	NULL
not	NULL
been	NULL
characterized	NULL
.	NULL

Although	NULL
in	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
,	NULL
and	NULL
numerous	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
several	NULL
activation	NULL
signals	NULL
simultaneously	NULL
induce	NULL
the	NULL
synthesis	NULL
of	NULL
II-2	NULL
as	NULL
well	NULL
as	NULL
II-4	NULL
RNA	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
there	NULL
are	NULL
numerous	NULL
other	NULL
signals	NULL
which	NULL
exert	NULL
contrasting	NULL
effects	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
1-2	NULL
and	NULL
I1-4	NULL
genes	NULL
and	NULL
the	NULL
production	NULL
of	NULL
both	NULL
lymphokines	NULL
.	NULL

Examples	NULL
of	NULL
the	NULL
latter	NULL
signals	NULL
include	NULL
agonists	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
and	NULL
steroid	NULL
hormones	NULL
.	NULL

Treatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
forskolin	NULL
or	NULL
prostaglandin	NULL
E	NULL
,	NULL
which	NULL
results	NULL
in	NULL
an	NULL
increase	NULL
of	NULL
intracellular	NULL
cyclic	NULL
AMP	NULL
levels	NULL
,	NULL
leads	NULL
to	NULL
the	NULL
suppression	NULL
of	NULL
1-2	NULL
production	NULL
while	NULL
it	NULL
fails	NULL
to	NULL
suppress	NULL
the	NULL
synthesis	NULL
of	NULL
I1-4	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

A	NULL
negative	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
and	NULL
I-2	NULL
production	NULL
has	NULL
also	NULL
been	NULL
described	NULL
for	NULL
glucocorticoid	NULL
hormones	NULL
in	NULL
several	NULL
T	NULL
cell	NULL
lines	NULL
and	NULL
splenic	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
latter	NULL
the	NULL
synthesis	NULL
of	NULL
I1-4	NULL
was	NULL
even	NULL
found	NULL
to	NULL
be	NULL
enhanced	NULL
after	NULL
glucocorticoid	NULL
administration	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
simultaneous	NULL
induction	NULL
of	NULL
H-2	NULL
and	NULL
II-4	NULL
genes	NULL
in	NULL
T	NULL
lymphocytes	NULL
might	NULL
be	NULL
regulated	NULL
through	NULL
sets	NULL
of	NULL
short	NULL
homologous	NULL
DNA	NULL
sequence	NULL
elements	NULL
which	NULL
have	NULL
been	NULL
detected	NULL
within	NULL
the	NULL
immediate	NULL
upstream	NULL
regions	NULL
of	NULL
murine	NULL
and	NULL
human	NULL
II-2	NULL
and	NULL
I1-4	NULL
genes	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

While	NULL
there	NULL
are	NULL
numerous	NULL
detailed	NULL
investigations	NULL
on	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
Il-2	NULL
genes	NULL
,	NULL
there	NULL
are	NULL
so	NULL
far	NULL
only	NULL
a	NULL
few	NULL
reports	NULL
about	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
I1-4	NULL
gene	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
.	NULL

Henkel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
have	NULL
*	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
*	NULL
On	NULL
leave	NULL
from	NULL
the	NULL
Shemyakin	NULL
Institute	NULL
of	NULL
Bioorganic	NULL
Chemistry	NULL
,	NULL
Vavilov	NULL
Street	NULL
,	NULL
Moscow	NULL
,	NULL
Russia	NULL
analysed	NULL
an	NULL
intronic	NULL
enhancer	NULL
of	NULL
the	NULL
murine	NULL
II-4	NULL
gene	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
I1-4	NULL
gene	NULL
in	NULL
mast	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Abe	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
have	NULL
investigated	NULL
one	NULL
sequence	NULL
element	NULL
from	NULL
the	NULL
human	NULL
II-4	NULL
promoter	NULL
.	NULL

This	NULL
element	NULL
was	NULL
designated	NULL
as	NULL
P	NULL
sequence	NULL
(	NULL
corresponding	NULL
Pu-bys	NULL
of	NULL
our	NULL
designation	NULL
:	NULL
see	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
and	NULL
thought	NULL
to	NULL
distinguish	NULL
the	NULL
activity	NULL
of	NULL
II-4	NULL
and	NULL
II-2	NULL
genes	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Li-Weber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
have	NULL
identified	NULL
T	NULL
cell-specific	NULL
negative	NULL
sequence	NULL
motifs	NULL
within	NULL
the	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
human	NULL
I1-4	NULL
gene	NULL
which	NULL
are	NULL
supposed	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
stringent	NULL
negative	NULL
control	NULL
of	NULL
I-4	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
analysed	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
murine	NULL
II-4	NULL
gene	NULL
in	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

We	NULL
identified	NULL
a	NULL
strong	NULL
transcriptional	NULL
enhancer	NULL
within	NULL
the	NULL
immediate	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
II-4	NULL
gene	NULL
which	NULL
shares	NULL
both	NULL
common	NULL
and	NULL
divergent	NULL
properties	NULL
with	NULL
the	NULL
promoter/enhancer	NULL
of	NULL
the	NULL
murine	NULL
1-2	NULL
gene	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
II-2	NULL
enhancer	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
enhancer	NULL
is	NULL
induced	NULL
by	NULL
phorbol	NULL
esters	NULL
,	NULL
Ca++	NULL
ionophores	NULL
and	NULL
plant	NULL
lectins	NULL
in	NULL
T	NULL
lymphoma	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
B	NULL
lymphoma	NULL
cells	NULL
or	NULL
HeLa	NULL
cells	NULL
.	NULL

Its	NULL
activity	NULL
is	NULL
suppressed	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
the	NULL
immunosuppressant	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
but	NULL
not-as	NULL
for	NULL
the	NULL
II-2	NULL
enhancer-by	NULL
agonists	NULL
of	NULL
PKA	NULL
.	NULL

The	NULL
II-4	NULL
promoter/enhancer	NULL
segment	NULL
is	NULL
bound	NULL
by	NULL
transcription	NULL
factors	NULL
which	NULL
were	NULL
also	NULL
identified	NULL
to	NULL
bind	NULL
and	NULL
to	NULL
control	NULL
the	NULL
II-2	NULL
enhancer	NULL
activity	NULL
,	NULL
such	NULL
as	NULL
NFAT-1	NULL
and	NULL
Octamer	NULL
factors	NULL
,	NULL
and	NULL
by	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
high	NULL
mobility	NULL
group	NULL
(	NULL
HMG	NULL
)	NULL
proteins	NULL
.	NULL

However	NULL
,	NULL
other	NULL
factors	NULL
which	NULL
also	NULL
control	NULL
the	NULL
1-2	NULL
enhancer	NULL
activity	NULL
,	NULL
in	NULL
particular	NULL
NF-xB	NULL
like	NULL
proteins	NULL
,	NULL
were	NULL
not	NULL
found	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
I1-4	NULL
promoter/enhancer	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
,	NULL
DNA	NULL
transfections	NULL
and	NULL
CAT	NULL
assays	NULL
Murine	NULL
E14	NULL
T	NULL
lymphoma	NULL
cells	NULL
,	NULL
human	NULL
Jurkat	NULL
T	NULL
lymphoma	NULL
cells	NULL
and	NULL
murine	NULL
P815	NULL
mastocytoma	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
to	NULL
densities	NULL
of	NULL
2-4	NULL
X	NULL
10Â°	NULL
cells	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
T	NULL
lymphoma	NULL
cells	NULL
were	NULL
transfected	NULL
using	NULL
a	NULL
modified	NULL
DEAE	NULL
dextran	NULL
sulfate	NULL
protocol	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
15	NULL
)	NULL
.	NULL

20	NULL
h	NULL
after	NULL
transfection	NULL
the	NULL
cells	NULL
were	NULL
divided	NULL
,	NULL
one	NULL
half	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
induced	NULL
with	NULL
the	NULL
phorbol	NULL
ester	NULL
TPA	NULL
(	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
;	NULL
10	NULL
ng	NULL
per	NULL
ml	NULL
)	NULL
and	NULL
the	NULL
Ca++	NULL
ionophore	NULL
ionomycin	NULL
(	NULL
0.5	NULL
4M	NULL
)	NULL
,	NULL
the	NULL
other	NULL
half	NULL
of	NULL
cells	NULL
was	NULL
used	NULL
as	NULL
uninduced	NULL
control	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
also	NULL
induced	NULL
by	NULL
ConA	NULL
(	NULL
Concanavalin	NULL
A	NULL
;	NULL
2.5	NULL
ug	NULL
per	NULL
ml	NULL
)	NULL
instead	NULL
of	NULL
ionomycin	NULL
and	NULL
,	NULL
in	NULL
addition	NULL
,	NULL
by	NULL
forskolin	NULL
(	NULL
5	NULL
aM	NULL
)	NULL
,	NULL
an	NULL
agonist	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
by	NULL
CsA	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

which	NULL
was	NULL
given	NULL
2	NULL
h	NULL
after	NULL
the	NULL
inducers	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
another	NULL
20	NULL
h	NULL
,	NULL
harvested	NULL
,	NULL
sonicated	NULL
and	NULL
the	NULL
CAT	NULL
activities	NULL
were	NULL
measured	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
densitiy	NULL
gradient	NULL
centrifugation	NULL
over	NULL
Ficoll/Metrizoate	NULL
and	NULL
the	NULL
T	NULL
lymphocytes	NULL
were	NULL
enriched	NULL
by	NULL
rosetting	NULL
(	NULL
16	NULL
)	NULL
.	NULL

DNA	NULL
cloning	NULL
Recombinant	NULL
DNA	NULL
work	NULL
was	NULL
done	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
.	NULL

The	NULL
series	NULL
of	NULL
IL4CAT	NULL
constructs	NULL
containing	NULL
various	NULL
DNA	NULL
segments	NULL
from	NULL
the	NULL
immediate	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
murine	NULL
II-4	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
was	NULL
obtained	NULL
by	NULL
cloning	NULL
the	NULL
fragment	NULL
of	NULL
the	NULL
construct	NULL
pMILS5	NULL
(	NULL
9	NULL
)	NULL
between	NULL
the	NULL
HindII/	NULL
BamHI	NULL
sites	NULL
of	NULL
the	NULL
CAT	NULL
vector	NULL
pBLCAT2	NULL
(	NULL
17	NULL
)	NULL
which	NULL
resulted	NULL
in	NULL
the	NULL
construct	NULL
IL4-797	NULL
(	NULL
containing	NULL
the	NULL
upstream	NULL
I-4	NULL
DNA	NULL
from	NULL
-12	NULL
to	NULL
-797	NULL
)	NULL
.	NULL

For	NULL
the	NULL
construction	NULL
of	NULL
CAT	NULL
plasmid	NULL
IL4-307	NULL
(	NULL
containing	NULL
the	NULL
upstream	NULL
DNA	NULL
from	NULL
-12	NULL
to	NULL
-307	NULL
)	NULL
,	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
5695	NULL
the	NULL
Psfl/Bgill	NULL
fragment	NULL
from	NULL
pMILS5	NULL
was	NULL
subcloned	NULL
into	NULL
pUC19	NULL
,	NULL
excised	NULL
as	NULL
a	NULL
Sphl/Xholl	NULL
fragment	NULL
and	NULL
subsequently	NULL
introduced	NULL
between	NULL
the	NULL
Sphl/BamHI	NULL
sites	NULL
of	NULL
pBLCAT2	NULL
.	NULL

Plasmid	NULL
1L4-6300	NULL
containing	NULL
the	NULL
upstream	NULL
DNA	NULL
sequences	NULL
from	NULL
-12	NULL
to	NULL
-6300	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
(	NULL
blunt	NULL
ended	NULL
)	NULL
EcoRI/HindIH	NULL
fragment	NULL
from	NULL
a	NULL
-6300pCAT	NULL
vector	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
M.	NULL
Brown	NULL
)	NULL
into	NULL
IL4-797	NULL
.	NULL

The	NULL
upstream	NULL
DNA	NULL
fragment	NULL
from	NULL
-12	NULL
to	NULL
-270	NULL
in	NULL
the	NULL
construct	NULL
IL4-270	NULL
was	NULL
synthesized	NULL
by	NULL
PCR	NULL
and	NULL
cloned	NULL
into	NULL
pBLCATS	NULL
(	NULL
which	NULL
was	NULL
constructed	NULL
by	NULL
P.Stein	NULL
,	NULL
Karlsruhe	NULL
,	NULL
and	NULL
lacks	NULL
an	NULL
inducible	NULL
TRE-like	NULL
element	NULL
within	NULL
the	NULL
plasmid	NULL
DNA	NULL
)	NULL
.	NULL

All	NULL
IL-4	NULL
promoter	NULL
segments	NULL
of	NULL
original	NULL
ILA4-CAT	NULL
plasmids	NULL
were	NULL
transfered	NULL
into	NULL
pBLCATS5	NULL
.	NULL

Construct	NULL
IL4-270	NULL
was	NULL
used	NULL
for	NULL
the	NULL
introduction	NULL
of	NULL
point	NULL
mutations	NULL
into	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
introduced	NULL
according	NULL
to	NULL
Higuchi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
by	NULL
PCR	NULL
using	NULL
the	NULL
following	NULL
mutated	NULL
primers	NULL
:	NULL
PU	NULL
â	NULL
bBM	NULL
:	NULL
AA	NULL
(	NULL
Positions	NULL
69	NULL
+70	NULL
)	NULL
;	NULL
5Â°	NULL
AATCTGGTGTAATAAAATTTTAAAATGTA-AACTCATTTTCCC	NULL
3	NULL
'	NULL
TT	NULL
(	NULL
69+70	NULL
)	NULL
:	NULL
5Â°	NULL
GGGAAAATGAGTTTACATTITAAAATTTTA-TTACACCAGATT	NULL
3	NULL
'	NULL
Pu-boy	NULL
:	NULL
AA	NULL
(	NULL
156+157	NULL
)	NULL
:	NULL
5	NULL
'	NULL
GAGAAACAGGTAAATTTTAATGTGAAATC-AGACCAATT	NULL
3	NULL
'	NULL
TT	NULL
(	NULL
156+157	NULL
)	NULL
:	NULL
5	NULL
'	NULL
AATTGGTCTGATTTCACATTAAAATTTACC-TGTTTCTC	NULL
3	NULL
'	NULL
Pu-boy	NULL
:	NULL
AA	NULL
(	NULL
235	NULL
+236	NULL
)	NULL
:	NULL
5	NULL
'	NULL
CGATTATGGTGTAATTTAATATGCTGAAAC-TTTGTAG	NULL
3	NULL
'	NULL
TT	NULL
(	NULL
235	NULL
+236	NULL
)	NULL
:	NULL
5Â°	NULL
CTACAAAGTTTCAGCATATTITAAATTACACC-ATAATCG	NULL
3	NULL
``	NULL
Mutations	NULL
into	NULL
Pu-b4	NULL
,	NULL
and	NULL
box	NULL
II	NULL
were	NULL
introduced	NULL
using	NULL
an	NULL
oligonucleotide-directed	NULL
mutagenesis	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
and	NULL
the	NULL
following	NULL
mutated	NULL
oligo-primers	NULL
:	NULL
AA	NULL
Pu-bay	NULL
:	NULL
5	NULL
'	NULL
TGAAACCAAGTTAAAATGAGTT	NULL
3	NULL
'	NULL
CC	NULL
BoxII	NULL
(	NULL
206+209+212	NULL
)	NULL
:5	NULL
'	NULL
CCCCCCCTTTGTTGTTGAAATCTACAAAG-	NULL
T	NULL
3	NULL
In	NULL
construct	NULL
IL-270	NULL
(	NULL
4M	NULL
)	NULL
,	NULL
the	NULL
underlined	NULL
TT	NULL
residues	NULL
of	NULL
purine	NULL
boxes	NULL
were	NULL
introduced	NULL
instead	NULL
of	NULL
two	NULL
G	NULL
residues	NULL
in	NULL
all	NULL
four	NULL
purine	NULL
boxes	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

Multiple	NULL
copies	NULL
of	NULL
Pu-b	NULL
,	NULL
,	NULL
Pu-bs	NULL
and	NULL
Pu-by	NULL
oy	NULL
(	NULL
the	NULL
sequences	NULL
see	NULL
below	NULL
)	NULL
containing	NULL
Sall	NULL
and	NULL
BamHI	NULL
linkers	NULL
were	NULL
cloned	NULL
in	NULL
front	NULL
of	NULL
the	NULL
tk	NULL
promoter	NULL
in	NULL
pBLCATS5	NULL
.	NULL

The	NULL
constructs	NULL
3	NULL
XPu-ba	NULL
,	NULL
3	NULL
XPu-bs	NULL
;	NULL
and	NULL
3	NULL
X	NULL
Pu-bg.oy	NULL
harbor	NULL
two	NULL
copies	NULL
of	NULL
Pu-boxes	NULL
in	NULL
the	NULL
orientation	NULL
of	NULL
CAT	NULL
gene	NULL
transcription	NULL
and	NULL
one	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
.	NULL

The	NULL
plasmid	NULL
IL4-270D	NULL
containing	NULL
the	NULL
1-4	NULL
promoter/enhancer	NULL
downstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
blunt-ended	NULL
EcoRI	NULL
-HindIII	NULL
fragment	NULL
of	NULL
IL4-270	NULL
into	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
pBLCATS5	NULL
.	NULL

Vectors	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
were	NULL
constructed	NULL
by	NULL
the	NULL
insertion	NULL
of	NULL
an	NULL
EcoRI	NULL
fragment	NULL
containing	NULL
the	NULL
complete	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
cDNA	NULL
(	NULL
19	NULL
)	NULL
into	NULL
the	NULL
expression	NULL
vector	NULL
pSGS	NULL
(	NULL
20	NULL
)	NULL
in	NULL
sense	NULL
or	NULL
anti-sense	NULL
orientation	NULL
.	NULL

DNA/protein	NULL
binding	NULL
studies	NULL
Whole-cell	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
prepared	NULL
from	NULL
3-10	NULL
g	NULL
packed	NULL
deep-frozen	NULL
cells	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA/ConA	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
dialysed	NULL
overnight	NULL
against	NULL
0.1	NULL
M	NULL
KCl	NULL
containing	NULL
TM	NULL
buffer	NULL
(	NULL
15	NULL
)	NULL
and	NULL
5696	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
passed	NULL
over	NULL
a	NULL
heparin/agarose	NULL
column	NULL
.	NULL

The	NULL
retarded	NULL
DNA	NULL
binding	NULL
proteins	NULL
were	NULL
eluted	NULL
by	NULL
0.4	NULL
M	NULL
KCl-containing	NULL
TM	NULL
buffer	NULL
and	NULL
used	NULL
in	NULL
DNasel	NULL
footprint	NULL
protection	NULL
experiments	NULL
as	NULL
described	NULL
earlier	NULL
.	NULL

In	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
(	NULL
EMSAs	NULL
)	NULL
,	NULL
crude	NULL
nuclear	NULL
protein	NULL
extracts	NULL
were	NULL
used	NULL
which	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
a	NULL
published	NULL
protocol	NULL
(	NULL
21	NULL
)	NULL
.	NULL

2	NULL
ug	NULL
protein	NULL
was	NULL
incubated	NULL
with	NULL
5000	NULL
cpm	NULL
(	NULL
equivalent	NULL
to	NULL
about	NULL
0.2	NULL
ng	NULL
)	NULL
of	NULL
a	NULL
P-labelled	NULL
oligonucleotide	NULL
probe	NULL
and	NULL
2	NULL
ug	NULL
poly	NULL
dI	NULL
-	NULL
dC	NULL
as	NULL
unspecific	NULL
inhibitor	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
20-30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
fractionated	NULL
on	NULL
non-denaturing	NULL
5	NULL
%	NULL
polyacrylamide	NULL
(	NULL
PAA	NULL
)	NULL
gels	NULL
at	NULL
200	NULL
V/15	NULL
cm	NULL
at	NULL
room	NULL
temperature	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

For	NULL
the	NULL
detection	NULL
of	NULL
binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
to	NULL
the	NULL
minor	NULL
groove	NULL
of	NULL
DNA	NULL
,	NULL
the	NULL
EMSAs	NULL
were	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
poly	NULL
dG	NULL
-	NULL
dC	NULL
instead	NULL
of	NULL
poly	NULL
dI	NULL
-	NULL
dC	NULL
as	NULL
unspecific	NULL
competitor	NULL
.	NULL

In	NULL
the	NULL
Oct-2A	NULL
antibody	NULL
experiment	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
antiserum	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
pre-incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
labelled	NULL
probe	NULL
.	NULL

The	NULL
Oct-2A	NULL
antibody	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
T.Wirth	NULL
)	NULL
was	NULL
raised	NULL
against	NULL
Vaccinia-expressed	NULL
Oct-2A	NULL
,	NULL
but	NULL
cross-reacted	NULL
weakly	NULL
with	NULL
Oct-1	NULL
as	NULL
well	NULL
.	NULL

In	NULL
the	NULL
supershift	NULL
experiments	NULL
,	NULL
the	NULL
following	NULL
AP-1-specific	NULL
antibodies	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
were	NULL
used	NULL
:	NULL
-c-Jun/AP-1	NULL
(	NULL
Cat	NULL
#	NULL
sc-44	NULL
)	NULL
,	NULL
Â«	NULL
-JunB	NULL
(	NULL
sc-73	NULL
)	NULL
,	NULL
Â«	NULL
-JunD	NULL
(	NULL
sc-74	NULL
)	NULL
,	NULL
Â«	NULL
-c-Fos	NULL
(	NULL
sc-52	NULL
)	NULL
,	NULL
Â«	NULL
-FosB	NULL
(	NULL
sc-48	NULL
)	NULL
,	NULL
e	NULL
Â«	NULL
-Fra-l1	NULL
(	NULL
sc-183	NULL
)	NULL
and	NULL
-Fra-2	NULL
(	NULL
sc-57	NULL
)	NULL
.	NULL

The	NULL
affinity	NULL
purfied	NULL
antibodies	NULL
were	NULL
added	NULL
shortly	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
one	NULL
h	NULL
on	NULL
ice	NULL
before	NULL
loading	NULL
on	NULL
the	NULL
PAA	NULL
gel	NULL
.	NULL

The	NULL
following	NULL
chemically	NULL
synthesized	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
(	NULL
nucleotides	NULL
of	NULL
restriction	NULL
enzyme	NULL
recognition	NULL
sites	NULL
are	NULL
written	NULL
in	NULL
lower	NULL
case	NULL
)	NULL
:	NULL
Murine	NULL
I1-4	NULL
promoter	NULL
:	NULL
Pu-ba	NULL
:	NULL
(	NULL
-60	NULL
)	NULL
tegaCTCATTTTCCCTTGGTTTCAG	NULL
(	NULL
-40	NULL
)	NULL
GAGTAAAAGGGAACCAAAGTCctag	NULL
Pu-by	NULL
:	NULL
(	NULL
~92	NULL
)	NULL
tegaCAATCTGGTGTAATAAAATTTTCCAATGTAA-ACTCAg	NULL
(	NULL
-57	NULL
)	NULL
GTTAGACCACATTATTTTAAAAGGTTACATTT-GAGTectag	NULL
(	NULL
=92	NULL
)	NULL
tcgaCAATCTGGTGTAATAAAATTTTAAAATGTAA-ACTCAg	NULL
(	NULL
-57	NULL
)	NULL
GTTAGACCACATTATTTTAAAATTTTACATTT-GAGTCctag	NULL
(	NULL
-92	NULL
)	NULL
tcgaCAATCTGGTGTAATAAAATTTTCCAATGTGG-ACTCAg	NULL
(	NULL
-57	NULL
)	NULL
GTTAGACCACATTATTTTAAAAGGTTACACC-TGAGTectag	NULL
Pu-be	NULL
:	NULL
(	NULL
-	NULL
176	NULL
)	NULL
tegaCAATTGGTCTGATTTCACAGGAAAATTTACC-TG	NULL
(	NULL
-	NULL
144	NULL
)	NULL
GTTAACCAGACTAAAGTGTCCTTTTAAATGG-ACctag	NULL
Pu-by	NULL
:	NULL
(	NULL
-252	NULL
)	NULL
tegaCTGAAAGGCCGATTATGGTGTAATTTCCTAT-GCTG	NULL
(	NULL
-228	NULL
)	NULL
GACTTTCCGGCTAATACCACATTAAAGGAT-ACGACctag	NULL
Box	NULL
I	NULL
:	NULL
(	NULL
-	NULL
116	NULL
)	NULL
tegacTGCTGATTGGCCCAGAATAACTG	NULL
(	NULL
-94	NULL
)	NULL
gACGACTAACCGGGTCTTATTGACctag	NULL
BoxII	NULL
:	NULL
(	NULL
-225	NULL
)	NULL
tegaCACTTTGTAGATTTAAAAAAAAAAGGGGGG-GGGAGGGGTGTTTCg	NULL
(	NULL
-	NULL
182	NULL
)	NULL
GTGAAACATCTAAATTTTTTTTTTCCCCCCC-CCTCCCCACAAAGectag	NULL
Ets-binding	NULL
site	NULL
of	NULL
murine	NULL
T	NULL
cell	NULL
receptor	NULL
a	NULL
chain	NULL
gene	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
:	NULL
NF-a4	NULL
:	NULL
__	NULL
agctATCCTCTGGAAAGAt	NULL
tTAGGAGACCTTTCTagate	NULL
Consensus	NULL
Octamer	NULL
site	NULL
from	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
:	NULL
Pu-bgcny	NULL
:	NULL
Pu-bg.om	NULL
:	NULL
Oct	NULL
:	NULL
ctagaAGCAGAAATGCAAATTATACCCG	NULL
CGTCTITACGTTTAATATGGGCitega	NULL
Consensus	NULL
AP-1	NULL
site	NULL
(	NULL
Converted	NULL
TREp	NULL
of	NULL
murine	NULL
II-2	NULL
enhancer	NULL
)	NULL
:	NULL
1531	NULL
;	NULL
(	NULL
-164	NULL
)	NULL
catgAAATTCCAGACAGTCATCAGcatg	NULL
(	NULL
-	NULL
143	NULL
)	NULL
TTTAAGGTCAGTCAGTAGTC	NULL
The	NULL
sequences	NULL
of	NULL
other	NULL
oligonucleotides	NULL
of	NULL
protein	NULL
binding	NULL
sites	NULL
from	NULL
the	NULL
I1-2	NULL
promoter	NULL
have	NULL
been	NULL
published	NULL
(	NULL
22	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Bacterially	NULL
expressed	NULL
GST-Octamer	NULL
fusion	NULL
proteins	NULL
containing	NULL
the	NULL
POU	NULL
domains	NULL
of	NULL
Oct-1	NULL
or	NULL
Oct-2	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
of	NULL
Smith	NULL
and	NULL
Johnson	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
pGEXOct	NULL
vectors	NULL
(	NULL
constructed	NULL
by	NULL
P.	NULL
Matthias	NULL
)	NULL
comprise	NULL
the	NULL
small	NULL
peptide	NULL
epitope	NULL
of	NULL
influenza	NULL
virus	NULL
hemagglutinin	NULL
protein	NULL
followed	NULL
by	NULL
the	NULL
Oct	NULL
POU	NULL
domains	NULL
in	NULL
GST-1	NULL
.	NULL

HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
was	NULL
isolated	NULL
from	NULL
Ehrlich	NULL
ascites	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
,	NULL
dialysed	NULL
against	NULL
buffer	NULL
D	NULL
containing	NULL
100	NULL
mM	NULL
KCl	NULL
and	NULL
fractionated	NULL
on	NULL
a	NULL
ffQ-Sepharose	NULL
column	NULL
which	NULL
was	NULL
eluted	NULL
in	NULL
a	NULL
stepwise	NULL
manner	NULL
with	NULL
buffer	NULL
D	NULL
containing	NULL
0.2	NULL
,	NULL
0.3	NULL
,	NULL
0.4	NULL
and	NULL
2	NULL
M	NULL
KCI	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
0.2	NULL
M	NULL
KCI	NULL
fraction	NULL
was	NULL
loaded	NULL
on	NULL
a	NULL
Hi	NULL
Trap-blue	NULL
column	NULL
(	NULL
Pharmacia	NULL
)	NULL
followed	NULL
by	NULL
stepwise	NULL
elution	NULL
with	NULL
buffer	NULL
D	NULL
containing	NULL
0.4	NULL
M	NULL
,	NULL
1.5	NULL
M	NULL
and	NULL
2	NULL
M	NULL
NaCl	NULL
.	NULL

The	NULL
1.5	NULL
M	NULL
fraction	NULL
was	NULL
dialysed	NULL
and	NULL
subsequently	NULL
fractionated	NULL
on	NULL
a	NULL
Mono	NULL
S	NULL
column	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

This	NULL
column	NULL
was	NULL
eluted	NULL
with	NULL
a	NULL
linear	NULL
gradient	NULL
from	NULL
0	NULL
to	NULL
2	NULL
M	NULL
NaCl	NULL
(	NULL
in	NULL
buffer	NULL
D	NULL
)	NULL
.	NULL

The	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
protein	NULL
was	NULL
eluted	NULL
between	NULL
0.9	NULL
M	NULL
and	NULL
1	NULL
M	NULL
NaCl	NULL
and	NULL
gave	NULL
rise	NULL
to	NULL
one	NULL
protein	NULL
band	NULL
of	NULL
approximately	NULL
18	NULL
kD	NULL
.	NULL

RNA	NULL
analyses	NULL
For	NULL
the	NULL
semiquantitative	NULL
determination	NULL
of	NULL
I1-4	NULL
and	NULL
I1-2	NULL
RNAs	NULL
in	NULL
E14	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
cytoplasmic	NULL
RNAs	NULL
were	NULL
extracted	NULL
according	NULL
to	NULL
a	NULL
slightly	NULL
modified	NULL
mini-preparation	NULL
technique	NULL
for	NULL
the	NULL
simultaneous	NULL
isolation	NULL
of	NULL
nuclear	NULL
proteins	NULL
and	NULL
cytoplasmic	NULL
RNA	NULL
(	NULL
21	NULL
)	NULL
.	NULL

One	NULL
ug	NULL
of	NULL
RNA	NULL
was	NULL
converted	NULL
into	NULL
cDNA	NULL
using	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
primers	NULL
and	NULL
AMV	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
.	NULL

PCR	NULL
reactions	NULL
were	NULL
set	NULL
up	NULL
with	NULL
1/25	NULL
of	NULL
the	NULL
cDNA	NULL
according	NULL
to	NULL
published	NULL
protocols	NULL
(	NULL
29	NULL
)	NULL
with	NULL
Taq	NULL
polymerase	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
the	NULL
following	NULL
primers	NULL
:	NULL
I1-2	NULL
:	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
ATGTACAGCATGCAGCTCGATC	NULL
3	NULL
``	NULL
5	NULL
3	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
GGCTTGTTGAGATGATGCTTTGACA	NULL
3	NULL
``	NULL
Ii-4	NULL
:	NULL
_	NULL
5	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
ATGGGTCTCAACCCCCAGCTAGT	NULL
3	NULL
3	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
GCTCTTTAGGCTTTCCAGGAAGTC	NULL
3	NULL
``	NULL
5	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
CCAGGTCATCACTATTGGCAACGA	NULL
3	NULL
'	NULL
3	NULL
'	NULL
primer	NULL
:	NULL
5Â°	NULL
GAGCAGTAATCTCCTTCTGCATCC	NULL
3	NULL
'	NULL
After	NULL
20-30	NULL
cycles	NULL
,	NULL
2.5	NULL
ul	NULL
of	NULL
samples	NULL
were	NULL
separated	NULL
on	NULL
2.5	NULL
%	NULL
agarose	NULL
gels	NULL
.	NULL

Using	NULL
these	NULL
primers	NULL
,	NULL
DNA	NULL
segments	NULL
of	NULL
502	NULL
bp	NULL
(	NULL
I-2	NULL
)	NULL
,	NULL
399	NULL
bp	NULL
(	NULL
I1-4	NULL
)	NULL
and	NULL
224	NULL
bp	NULL
(	NULL
actin	NULL
)	NULL
were	NULL
synthesized	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Actin	NULL
:	NULL
RESULTS	NULL
The	NULL
transcription	NULL
of	NULL
the	NULL
II-4	NULL
gene	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
controlled	NULL
by	NULL
an	NULL
inducible	NULL
enhancer	NULL
In	NULL
E14	NULL
T	NULL
lymphoma	NULL
cells	NULL
II-4	NULL
and	NULL
II-2	NULL
mRNAs	NULL
are	NULL
synthesized	NULL
upon	NULL
induction	NULL
by	NULL
the	NULL
phorbolester	NULL
TPA	NULL
and	NULL
the	NULL
lectin	NULL
Concanavalin	NULL
A	NULL
(	NULL
ConA	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
study	NULL
the	NULL
II-4	NULL
promoter	NULL
activity	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
we	NULL
constructed	NULL
several	NULL
CAT	NULL
reporter	NULL
plasmids	NULL
containing	NULL
various	NULL
segments	NULL
of	NULL
upstream	NULL
DNA	NULL
of	NULL
the	NULL
murine	NULL
I-4	NULL
gene	NULL
.	NULL

A	NULL
CAT	NULL
construct	NULL
containing	NULL
the	NULL
immediate	NULL
upstream	NULL
segment	NULL
from	NULL
nucleotide	NULL
position	NULL
-12	NULL
to	NULL
-270	NULL
,	NULL
designated	NULL
as	NULL
IL4-270	NULL
,	NULL
exhibited	NULL
a	NULL
strong	NULL
inducible	NULL
promoter	NULL
activity	NULL
upon	NULL
transfection	NULL
into	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
,	NULL
El4	NULL
cells	NULL
.	NULL

Its	NULL
activity	NULL
was	NULL
induced	NULL
by	NULL
TPA	NULL
,	NULL
TPA/ConA	NULL
,	NULL
TPA/ionomycin	NULL
or	NULL
TPA/ionomycin/forskolin	NULL
treatment	NULL
,	NULL
and	NULL
its	NULL
induction	NULL
was	NULL
efficiently	NULL
suppressed	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
the	NULL
c	NULL
A20J	NULL
HeLa	NULL
mss	NULL
30	NULL
201	NULL
CAT-activity	NULL
(	NULL
%	NULL
acetylation	NULL
)	NULL
U	NULL
IL4-270	NULL
Â§xTREcoll	NULL
114-270	NULL
5xTREcoll	NULL
1L4-270	NULL
5xTREcoll	NULL
C	NULL
100f7	NULL
C	NULL
270	NULL
|_	NULL
1	NULL
|	NULL
a	NULL
_|	NULL
-	NULL
Oc	NULL
Â§	NULL
Â©	NULL
]	NULL
Â®	NULL
m	NULL
cee	NULL
,	NULL
&	NULL
|	NULL
797	NULL
Â§	NULL
so	NULL
!	NULL

g	NULL
601	NULL
|	NULL
a	NULL
|	NULL
|	NULL
_	NULL
|	NULL
|	NULL
P	NULL
..	NULL
|	NULL
&	NULL
401	NULL
|	NULL
5	NULL
|	NULL
270D	NULL
|	NULL
$	NULL
1	NULL
i	NULL
|	NULL
|	NULL
|	NULL
Â»	NULL
|	NULL
S	NULL
201	NULL
307	NULL
|	NULL
|	NULL
-	NULL
6300	NULL
|	NULL
|	NULL
(	NULL
m	NULL
m	NULL
|	NULL
I	NULL
P-	NULL
|	NULL
flee	NULL
_	NULL
B	NULL
R	NULL
|H	NULL
IL4-6300	NULL
_	NULL
IL4-797	NULL
-	NULL
114-307	NULL
1L4-270	NULL
1L4-270D	NULL
Figure	NULL
1	NULL
.	NULL

Detection	NULL
of	NULL
II-4	NULL
promoter/enhancer	NULL
activity	NULL
in	NULL
El4	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Detection	NULL
of	NULL
accumulation	NULL
of	NULL
I1-2	NULL
and	NULL
II-4	NULL
mRNAs	NULL
in	NULL
activated	NULL
El4	NULL
cells	NULL
by	NULL
the	NULL
PCR-RT	NULL
technique	NULL
.	NULL

As	NULL
indicated	NULL
,	NULL
El4	NULL
cells	NULL
were	NULL
induced	NULL
by	NULL
TPA/ConA	NULL
for	NULL
45	NULL
min	NULL
to	NULL
30	NULL
h.	NULL
Their	NULL
cytoplasmic	NULL
RNAs	NULL
were	NULL
isolated	NULL
and	NULL
reverse-transcribed	NULL
.	NULL

PCR	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
specific	NULL
DNA	NULL
primers	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
actin	NULL
RNA	NULL
(	NULL
lanes	NULL
1	NULL
)	NULL
,	NULL
II-2	NULL
RNA	NULL
(	NULL
lanes	NULL
2	NULL
)	NULL
or	NULL
II-4	NULL
RNA	NULL
(	NULL
lanes	NULL
3	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

After	NULL
30	NULL
cycles	NULL
,	NULL
2.5	NULL
al	NULL
of	NULL
samples	NULL
were	NULL
analysed	NULL
by	NULL
fractionation	NULL
on	NULL
2.5	NULL
%	NULL
agarose	NULL
gels	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
for	NULL
details	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
I1-4	NULL
promoter	NULL
is	NULL
inducible	NULL
in	NULL
El4	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
A20J	NULL
B	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

The	NULL
construct	NULL
IL4-270	NULL
containing	NULL
the	NULL
I1-4	NULL
promoter	NULL
from	NULL
-12	NULL
to	NULL
-270	NULL
was	NULL
transfected	NULL
into	NULL
El4	NULL
cells	NULL
and	NULL
A20J	NULL
B	NULL
cells	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
or	NULL
in	NULL
HeLa	NULL
cells	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
co-precipitation	NULL
method	NULL
.	NULL

20	NULL
h	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
divided	NULL
.	NULL

One	NULL
part	NULL
was	NULL
left	NULL
as	NULL
uninduced	NULL
control	NULL
,	NULL
other	NULL
parts	NULL
of	NULL
cells	NULL
were	NULL
induced	NULL
by	NULL
TPA/ionomycin	NULL
(	NULL
T/	NULL
;	NULL
El4	NULL
,	NULL
A20	NULL
)	NULL
and	NULL
HeLa	NULL
cells	NULL
)	NULL
or	NULL
by	NULL
TPA	NULL
alone	NULL
(	NULL
TPA	NULL
)	NULL
,	NULL
forskolin	NULL
alone	NULL
(	NULL
F	NULL
)	NULL
,	NULL
TPA/ConA	NULL
(	NULL
T/ConA	NULL
)	NULL
,	NULL
TPA/ionomycin/forskolin	NULL
(	NULL
T/L/F	NULL
)	NULL
or	NULL
TPA/ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
(	NULL
T/I+CsA	NULL
)	NULL
.	NULL

20	NULL
h	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
CAT	NULL
assays	NULL
were	NULL
done	NULL
as	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
mean	NULL
values	NULL
of	NULL
two	NULL
(	NULL
A20J	NULL
B	NULL
and	NULL
HeLa	NULL
cells	NULL
)	NULL
or	NULL
four	NULL
(	NULL
El4	NULL
cells	NULL
)	NULL
independent	NULL
transfection	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
immediate	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
II-4	NULL
gene	NULL
harbors	NULL
a	NULL
strong	NULL
inducible	NULL
enhancer	NULL
.	NULL

The	NULL
indicated	NULL
I4/CAT	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
El4	NULL
cells	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
.	NULL

After	NULL
20	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
divided	NULL
.	NULL

One-half	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
incubated	NULL
for	NULL
20	NULL
h	NULL
with	NULL
TPA/ionomycin	NULL
(	NULL
T/D	NULL
,	NULL
the	NULL
other	NULL
half	NULL
was	NULL
left	NULL
as	NULL
uninduced	NULL
control	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
mean	NULL
values	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
.	NULL

All	NULL
T4/CAT	NULL
plasmids	NULL
were	NULL
constructed	NULL
using	NULL
pBLCATS5	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
construct	NULL
IL4-270D	NULL
contains	NULL
one	NULL
copy	NULL
of	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
(	NULL
from	NULL
position	NULL
-12	NULL
to	NULL
-270	NULL
)	NULL
downstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

The	NULL
other	NULL
constructs	NULL
contain	NULL
the	NULL
indicated	NULL
segments	NULL
of	NULL
II-4	NULL
upstream	NULL
DNA	NULL
in	NULL
front	NULL
of	NULL
the	NULL
tk	NULL
promoter	NULL
and	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
orientation	NULL
of	NULL
CAT	NULL
transcription	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
5697	NULL
EL-4+	NULL
TCE	NULL
BP8154	NULL
B	NULL
EL-4+	NULL
TCE	NULL
A	NULL
B.	NULL
WW	NULL
6	NULL
9	NULL
a	NULL
6	NULL
G	NULL
B	NULL
i	NULL
2	NULL
3	NULL
aB	NULL
12	NULL
3	NULL
4	NULL
.o	NULL
*	NULL
Â®	NULL
5	NULL
``	NULL
/	NULL
wit	NULL
wee	NULL
H	NULL
~	NULL
l	NULL
â	NULL
â	NULL
a	NULL
.	NULL

*	NULL
as	NULL
wan	NULL
we	NULL
w	NULL
Â»	NULL
-	NULL
104	NULL
-	NULL
#	NULL
4	NULL
~~	NULL
@	NULL
,	NULL
.	NULL

4	NULL
-128-	NULL
.	NULL

``	NULL
â	NULL
Fo	NULL
-171	NULL
~	NULL
Â¢	NULL
gg	NULL
ts	NULL
Fo	NULL
ise	NULL
.	NULL

ts	NULL
16	NULL
the	NULL
MB	NULL
3	NULL
Â«	NULL
Â®	NULL
5	NULL
~	NULL
~	NULL
ite	NULL
a	NULL
.	NULL

-	NULL
144	NULL
<	NULL
0	NULL
-|	NULL
*=	NULL
wite	NULL
a.	NULL
!	NULL

i	NULL
lle	NULL
mo	NULL
-183	NULL
``	NULL
-	NULL
126Â°	NULL
i	NULL
ih	NULL
*	NULL
H	NULL
-	NULL
108+	NULL
@	NULL
@	NULL
II	NULL
-	NULL
224	NULL
t	NULL
86	NULL
m	NULL
8	NULL
=	NULL
Â®	NULL
a	NULL
-	NULL
235	NULL
3	NULL
o	NULL
a	NULL
.	NULL

2	NULL
-	NULL
65	NULL
.	NULL

@	NULL
_	NULL
&	NULL
m	NULL
-253	NULL
0	NULL
%	NULL
<	NULL
E=	NULL
3	NULL
262	NULL
-	NULL
%	NULL
#	NULL
c.	NULL
#	NULL
%	NULL
-	NULL
40	NULL
-	NULL
Â«	NULL
Figure	NULL
2	NULL
.	NULL

Detection	NULL
of	NULL
binding	NULL
of	NULL
protein	NULL
factors	NULL
to	NULL
the	NULL
I1-4	NULL
promoter/enhancer	NULL
by	NULL
DNase	NULL
I	NULL
footprinting	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DNase	NULL
I	NULL
footprint	NULL
protection	NULL
of	NULL
proximal	NULL
II-4	NULL
promoter	NULL
DNA	NULL
by	NULL
protein	NULL
extract	NULL
from	NULL
E14	NULL
T	NULL
cells	NULL
enriched	NULL
by	NULL
heparin-agarose	NULL
column	NULL
chromatography	NULL
and	NULL
an	NULL
enriched	NULL
TCEp	NULL
protein	NULL
preparation	NULL
.	NULL

An	NULL
I1-4	NULL
promoter	NULL
DNA	NULL
probe	NULL
(	NULL
labelled	NULL
at	NULL
the	NULL
EcoRI	NULL
site	NULL
near	NULL
nucleotide	NULL
position	NULL
-12	NULL
in	NULL
construct	NULL
IL4-307	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
50	NULL
ug	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
100	NULL
ug	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
of	NULL
partially	NULL
purified	NULL
extract	NULL
from	NULL
El4	NULL
T	NULL
cells	NULL
induced	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA/ConA	NULL
(	NULL
10	NULL
ng/ml	NULL
,	NULL
2.5	NULL
ug/m	NULL
!	NULL
)	NULL

.	NULL

In	NULL
lane	NULL
3	NULL
,	NULL
the	NULL
promoter	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
TCEp-protein	NULL
preparation	NULL
which	NULL
,	NULL
after	NULL
fractionation	NULL
on	NULL
heparin-agarose	NULL
and	NULL
Sephacryl	NULL
$	NULL
300	NULL
columns	NULL
,	NULL
was	NULL
enriched	NULL
by	NULL
chromatography	NULL
on	NULL
an	NULL
affinity	NULL
column	NULL
containing	NULL
multimers	NULL
of	NULL
TCEp	NULL
motif	NULL
of	NULL
I1-2	NULL
enhancer	NULL
(	NULL
see	NULL
26	NULL
)	NULL
.	NULL

G	NULL
=	NULL
G-specific	NULL
sequencing	NULL
reaction	NULL
.	NULL

B	NULL
=	NULL
Control	NULL
lane	NULL
containing	NULL
25	NULL
ug	NULL
bovine	NULL
serum	NULL
albumin	NULL
in	NULL
the	NULL
footprint	NULL
reaction	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Detection	NULL
of	NULL
binding	NULL
of	NULL
protein	NULL
factors	NULL
to	NULL
the	NULL
distal	NULL
I1-4	NULL
promoter	NULL
DNA	NULL
.	NULL

An	NULL
II-4	NULL
promoter	NULL
probe	NULL
(	NULL
labelled	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
near	NULL
position	NULL
-307	NULL
in	NULL
IL4-307	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
50	NULL
ug	NULL
protein	NULL
from	NULL
induced	NULL
E14	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
50	NULL
ug	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
100	NULL
ug	NULL
protein	NULL
from	NULL
P815	NULL
mast	NULL
cells	NULL
induced	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
4	NULL
,	NULL
the	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
TCEp	NULL
protein	NULL
(	NULL
see	NULL
above	NULL
and	NULL
Materials	NULL
and	NULL
Methods	NULL
}	NULL
.	NULL

immunosuppressant	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
construct	NULL
remained	NULL
transcriptionally	NULL
inactive	NULL
in	NULL
A20J	NULL
B	NULL
lymphoma	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
this	NULL
DNA	NULL
segment	NULL
was	NULL
also	NULL
induced	NULL
from	NULL
a	NULL
position	NULL
downstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
as	NULL
in	NULL
construct	NULL
IL4-270D	NULL
,	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
shows	NULL
the	NULL
typical	NULL
properties	NULL
of	NULL
a	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

Since	NULL
point	NULL
mutations	NULL
at	NULL
numerous	NULL
sites	NULL
of	NULL
the	NULL
enhancer	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
of	NULL
its	NULL
activity	NULL
,	NULL
the	NULL
minimal	NULL
size	NULL
of	NULL
the	NULL
Il-4	NULL
promoter/enhancer	NULL
spans	NULL
approximately	NULL
260	NULL
bp	NULL
DNA	NULL
,	NULL
i.e	NULL
.	NULL

it	NULL
is	NULL
of	NULL
a	NULL
similar	NULL
size	NULL
to	NULL
the	NULL
murine	NULL
II-2	NULL
enhancer	NULL
(	NULL
275	NULL
bp	NULL
;	NULL
15	NULL
)	NULL
.	NULL

However	NULL
,	NULL
while	NULL
the	NULL
DNA	NULL
sequences	NULL
upstream	NULL
of	NULL
the	NULL
II-2	NULL
enhancer	NULL
exert	NULL
only	NULL
a	NULL
minor	NULL
effect	NULL
on	NULL
its	NULL
inducible	NULL
activity	NULL
in	NULL
T	NULL
lymphoma	NULL
cells	NULL
(	NULL
15	NULL
,	NULL
30	NULL
)	NULL
,	NULL
those	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
I1-4	NULL
enhancer	NULL
are	NULL
crucial	NULL
for	NULL
its	NULL
activity	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
human	NULL
I-4	NULL
promoter	NULL
(	NULL
14	NULL
)	NULL
,	NULL
the	NULL
sequences	NULL
between	NULL
-270	NULL
and	NULL
-307	NULL
suppress	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
murine	NULL
II-4	NULL
promoter	NULL
since	NULL
the	NULL
construct	NULL
IL4-307	NULL
containing	NULL
this	NULL
DNA	NULL
segment	NULL
showed	NULL
only	NULL
one	NULL
fifth	NULL
of	NULL
CAT	NULL
activity	NULL
compared	NULL
to	NULL
the	NULL
construct	NULL
14-270	NULL
.	NULL

This	NULL
suppression	NULL
is	NULL
partly	NULL
relieved	NULL
by	NULL
additional	NULL
positively	NULL
acting	NULL
elements	NULL
located	NULL
further	NULL
upstream	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
5698	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
38	NULL
|	NULL
...	NULL
I~	NULL
{	NULL
(	NULL
``	NULL
I	NULL
Itithu	NULL
Ch	NULL
an	NULL
ats	NULL
an	NULL
ass	NULL
+	NULL
Figure	NULL
3	NULL
.	NULL

The	NULL
II-4	NULL
Pu-boxes	NULL
are	NULL
NFAT-1	NULL
binding	NULL
sites	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Similar	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
Pu-by	NULL
and	NULL
Pu-by	NULL
of	NULL
I1-2	NULL
and	NULL
II-4	NULL
promoters	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
Pu-b	NULL
,	NULL
DNA	NULL
probe	NULL
(	NULL
lanes	NULL
1-10	NULL
)	NULL
,	NULL
a	NULL
probe	NULL
(	NULL
lanes	NULL
11-20	NULL
)	NULL
,	NULL
a	NULL
Pu-boxg	NULL
probe	NULL
carrying	NULL
two	NULL
point	NULL
mutations	NULL
within	NULL
the	NULL
two	NULL
central	NULL
G	NULL
residues	NULL
(	NULL
Pu-bg.yy	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
(	NULL
lanes	NULL
21-24	NULL
)	NULL
and	NULL
a	NULL
UPS	NULL
probe	NULL
of	NULL
the	NULL
I1-2	NULL
promoter	NULL
(	NULL
lane	NULL
25	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
2	NULL
ug	NULL
crude	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
E14	NULL
cells	NULL
(	NULL
-	NULL
)	NULL
,	NULL
from	NULL
cells	NULL
induced	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA/ionomycin	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
ng/ml	NULL
CsA	NULL
(	NULL
+/C	NULL
)	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
2	NULL
ug	NULL
poly	NULL
dI.dC	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
17	NULL
,	NULL
21	NULL
,	NULL
22	NULL
and	NULL
25	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
50	NULL
ng	NULL
of	NULL
indicated	NULL
Pu-box	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
3-5	NULL
,	NULL
13-15	NULL
,	NULL
19	NULL
and	NULL
24	NULL
)	NULL
,	NULL
the	NULL
UPS	NULL
of	NULL
I1-2	NULL
promoter	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
16	NULL
)	NULL
,	NULL
a	NULL
perfect	NULL
Octamer	NULL
binding	NULL
site	NULL
(	NULL
lanes	NULL
7.9	NULL
,	NULL
18	NULL
and	NULL
23	NULL
)	NULL
or	NULL
an	NULL
AP-1	NULL
consensus	NULL
site	NULL
(	NULL
153	NULL
T	NULL
:	NULL
lanes	NULL
10	NULL
and	NULL
20	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
Pu-b	NULL
,	NULL
is	NULL
a	NULL
NFAT-1	NULL
binding	NULL
site	NULL
.	NULL

A	NULL
Pu-b	NULL
,	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
El4	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
from	NULL
El4	NULL
cells	NULL
induced	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA/ionomycin	NULL
(	NULL
lanes	NULL
2-18	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
5	NULL
ng	NULL
(	NULL
odd	NULL
lanes	NULL
)	NULL
or	NULL
50	NULL
ng	NULL
(	NULL
even	NULL
lanes	NULL
)	NULL
of	NULL
indicated	NULL
Pu-boxes	NULL
(	NULL
lanes	NULL
3-10	NULL
and	NULL
15-18	NULL
)	NULL
,	NULL
an	NULL
Ets	NULL
binding	NULL
site	NULL
(	NULL
NF-4	NULL
:	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
or	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
153	NULL
T	NULL
:	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
.	NULL

The	NULL
Pu-bg.oy	NULL
oligonucleotide	NULL
contains	NULL
two	NULL
point	NULL
mutations	NULL
within	NULL
its	NULL
non-canonical	NULL
Octamer	NULL
site	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
Pu-be	NULL
is	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
NFAT-1	NULL
and	NULL
Octamer	NULL
factors	NULL
.	NULL

A	NULL
Pu-be	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
of	NULL
uninduced	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
induced	NULL
El4	NULL
cells	NULL
(	NULL
lanes	NULL
2-18	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
3-18	NULL
)	NULL
of	NULL
5	NULL
ng	NULL
(	NULL
odd	NULL
lanes	NULL
)	NULL
or	NULL
50	NULL
ng	NULL
(	NULL
even	NULL
lanes	NULL
)	NULL
of	NULL
indicated	NULL
Pu-box	NULL
nucleotides	NULL
(	NULL
lanes	NULL
3-6	NULL
,	NULL
9,10	NULL
,	NULL
15-18	NULL
)	NULL
,	NULL
a	NULL
consensus	NULL
Octamer	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
,	NULL
Ets	NULL
(	NULL
NF-o4	NULL
:	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
or	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
153T	NULL
:	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
.	NULL

F	NULL
=	NULL
free	NULL
probe	NULL
.	NULL

The	NULL
NFAT-1	NULL
and	NULL
Octamer	NULL
factor	NULL
complexes	NULL
are	NULL
indicated	NULL
.	NULL

construct	NULL
14-797	NULL
containing	NULL
the	NULL
sequences	NULL
to	NULL
-797	NULL
was	NULL
3-4	NULL
mastocytoma	NULL
cells	NULL
and	NULL
non-lymphoid	NULL
HeLa	NULL
cells	NULL
for	NULL
DNA/protein	NULL
times	NULL
more	NULL
active	NULL
than	NULL
construct	NULL
IL4-307	NULL
.	NULL

Additional	NULL
negatively	NULL
binding	NULL
studies	NULL
.	NULL

Whole	NULL
cellular	NULL
protein	NULL
extracts	NULL
were	NULL
passed	NULL
acting	NULL
sequence	NULL
elements	NULL
are	NULL
located	NULL
further	NULL
upstream	NULL
because	NULL
through	NULL
heparin/agarose	NULL
columns	NULL
,	NULL
the	NULL
retarded	NULL
DNA	NULL
binding	NULL
the	NULL
DNA	NULL
sequences	NULL
from	NULL
-797	NULL
to	NULL
-6300	NULL
(	NULL
in	NULL
construct	NULL
IL4-6300	NULL
)	NULL
proteins	NULL
were	NULL
eluted	NULL
by	NULL
0.4	NULL
M	NULL
KCl	NULL
and	NULL
used	NULL
in	NULL
DNasel	NULL
footprint	NULL
had	NULL
a	NULL
strong	NULL
suppressive	NULL
effect	NULL
on	NULL
the	NULL
Il-4	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

protection	NULL
assays	NULL
with	NULL
the	NULL
Il-4	NULL
promoter	NULL
DNA	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
.	NULL

.	NULL

several	NULL
transcription	NULL
factors	NULL
known	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
Il-2	NULL
promoter	NULL
Multiple	NULL
purine	NULL
boxes	NULL
are	NULL
part	NULL
of	NULL
the	NULL
I1-4	NULL
promoter	NULL
(	NULL
such	NULL
as	NULL
AP-1	NULL
,	NULL
AP-3	NULL
,	NULL
NF-xB	NULL
and	NULL
Octamer	NULL
factors	NULL
)	NULL
were	NULL
also	NULL
In	NULL
order	NULL
to	NULL
investigate	NULL
which	NULL
sites	NULL
of	NULL
the	NULL
promoter	NULL
are	NULL
used	NULL
in	NULL
the	NULL
footprint	NULL
assays	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
recognized	NULL
by	NULL
DNA	NULL
binding	NULL
proteins	NULL
we	NULL
prepared	NULL
protein	NULL
extracts	NULL
revealed	NULL
six	NULL
promoter	NULL
sites	NULL
as	NULL
targets	NULL
for	NULL
DNA	NULL
binding	NULL
proteins	NULL
from	NULL
lymphoid	NULL
El4	NULL
T	NULL
cells	NULL
and	NULL
70Z	NULL
pre-B	NULL
cells	NULL
,	NULL
myeloid	NULL
P815	NULL
from	NULL
lymphoid	NULL
(	NULL
E14	NULL
)	NULL
and	NULL
myeloid	NULL
(	NULL
P815	NULL
)	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Four	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
5699	NULL
A	NULL
.	NULL

B.	NULL
ber	NULL
TREcop	NULL
--	NULL
--	NULL
--	NULL
Oct__	NULL
;	NULL
____Pi-bg	NULL
...	NULL
_.._.	NULL
;	NULL
â	NULL
|	NULL
oa	NULL
)	NULL
|	NULL
$	NULL
aP	NULL
%	NULL
a-Oct-2A	NULL
a-Oct-2A	NULL
$	NULL
!	NULL

$	NULL
@	NULL
I	NULL
cg	NULL
!	NULL

+*|	NULL
~	NULL
``	NULL
-|3	NULL
I	NULL
$	NULL
``	NULL
|y	NULL
``	NULL
|8	NULL
I+	NULL
``	NULL
|	NULL
<	NULL
``	NULL
[	NULL
s	NULL
|	NULL
{	NULL
ii	NULL
=	NULL
--	NULL
L_	NULL
IP..	NULL
~*'-	NULL
@	NULL
00000e0008000000=0	NULL
o-	NULL
.	NULL

Oct-2Be	NULL
Oct-2Ae	NULL
Oct-1	NULL
NFAT-1	NULL
Oct-2A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10111213	NULL
1415	NULL
1617	NULL
I	NULL
â	NULL
u-bB	NULL
â	NULL
ï¬ï¬	NULL
wa	NULL
wa	NULL
#	NULL
i	NULL
-	NULL
NFAT-1	NULL
Â«	NULL
#	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
Figure	NULL
4	NULL
.	NULL

Fra-2	NULL
is	NULL
a	NULL
prominent	NULL
component	NULL
of	NULL
NFAT-1	NULL
binding	NULL
to	NULL
the	NULL
Pu-by	NULL
of	NULL
I1-4	NULL
promoter	NULL
.	NULL

Supershift	NULL
assays	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Supershift	NULL
assays	NULL
with	NULL
Jun/Fos	NULL
specific	NULL
antibodies	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
from	NULL
El4	NULL
cells	NULL
induced	NULL
for	NULL
3	NULL
h	NULL
with	NULL
TPA/ionomcin	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
TREcoll	NULL
probe	NULL
(	NULL
lanes	NULL
above	NULL
)	NULL
or	NULL
a	NULL
Pu-by	NULL
probe	NULL
(	NULL
below	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
2-15	NULL
0.5	NULL
pl	NULL
(	NULL
even	NULL
lanes	NULL
)	NULL
or	NULL
2	NULL
l	NULL
(	NULL
odd	NULL
lanes	NULL
)	NULL
of	NULL
the	NULL
respective	NULL
Jun/Fos	NULL
specific	NULL
antibodies	NULL
were	NULL
added	NULL
shortly	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
EMSAs	NULL
,	NULL
followed	NULL
by	NULL
one	NULL
h	NULL
incubation	NULL
on	NULL
ice	NULL
.	NULL

In	NULL
lanes	NULL
1	NULL
,	NULL
16	NULL
and	NULL
17	NULL
no	NULL
antibodies	NULL
were	NULL
added	NULL
.	NULL

For	NULL
competition	NULL
,	NULL
in	NULL
lane	NULL
16	NULL
,	NULL
a	NULL
25	NULL
fold	NULL
molar	NULL
excess	NULL
of	NULL
TREcoll	NULL
(	NULL
above	NULL
)	NULL
or	NULL
Pu-by	NULL
(	NULL
below	NULL
)	NULL
was	NULL
addedd	NULL
,	NULL
in	NULL
lane	NULL
17	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
Oct	NULL
DNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSAs	NULL
with	NULL
an	NULL
a-Oct-2A	NULL
specific	NULL
antibody	NULL
.	NULL

Nuclear	NULL
proteins	NULL
of	NULL
El4	NULL
cells	NULL
induced	NULL
for	NULL
3	NULL
h	NULL
with	NULL
TPA/ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
an	NULL
Oct	NULL
probe	NULL
(	NULL
lanes	NULL
1-5	NULL
)	NULL
or	NULL
an	NULL
Pu-by	NULL
probe	NULL
(	NULL
lanes	NULL
6-11	NULL
)	NULL
.	NULL

As	NULL
indicated	NULL
the	NULL
assays	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
a-Oct-2A	NULL
antiserum	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
probe	NULL
.	NULL

The	NULL
-Oct-2A	NULL
antibody	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
T.	NULL
Wirth	NULL
)	NULL
was	NULL
raised	NULL
against	NULL
Vaccinia	NULL
expressed	NULL
Oct-2A	NULL
and	NULL
reacts	NULL
weakly	NULL
with	NULL
Oct-1	NULL
as	NULL
well	NULL
.	NULL

In	NULL
lanes	NULL
1	NULL
,	NULL
6	NULL
and	NULL
11	NULL
no	NULL
antiserum	NULL
was	NULL
added	NULL
.	NULL

For	NULL
competition	NULL
,	NULL
in	NULL
lane	NULL
11	NULL
,	NULL
a	NULL
50	NULL
fold	NULL
molar	NULL
excess	NULL
of	NULL
Oct	NULL
DNA	NULL
was	NULL
added	NULL
.	NULL

of	NULL
these	NULL
sites	NULL
carry	NULL
the	NULL
motif	NULL
GGAAA	NULL
which	NULL
is	NULL
also	NULL
part	NULL
of	NULL
two	NULL
purine	NULL
boxes	NULL
within	NULL
the	NULL
murine	NULL
II-2	NULL
promoter	NULL
(	NULL
31	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
purine	NULL
boxes	NULL
of	NULL
1-2	NULL
and	NULL
II-4	NULL
promoters	NULL
are	NULL
bound	NULL
by	NULL
similar	NULL
factors	NULL
.	NULL

In	NULL
analogy	NULL
to	NULL
the	NULL
I1-2	NULL
purine	NULL
boxes	NULL
,	NULL
we	NULL
designated	NULL
the	NULL
four	NULL
II-4	NULL
purine	NULL
boxes	NULL
as	NULL
Pu-b	NULL
,	NULL
,	NULL
Pu-bs	NULL
,	NULL
and	NULL
Pu-bp	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
Pu-boxes	NULL
were	NULL
partially	NULL
protected	NULL
by	NULL
proteins	NULL
from	NULL
HeLa	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
two	NULL
non-Pu-boxes	NULL
which	NULL
we	NULL
designated	NULL
as	NULL
boxes	NULL
I	NULL
and	NULL
HI	NULL
were	NULL
completely	NULL
protected	NULL
by	NULL
proteins	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
boxes	NULL
I	NULL
and	NULL
II	NULL
are	NULL
bound	NULL
by	NULL
ubiquitous	NULL
factors	NULL
,	NULL
whereas	NULL
the	NULL
purine	NULL
boxes	NULL
appear	NULL
to	NULL
be	NULL
recognized	NULL
by	NULL
cell	NULL
type-specific	NULL
factors	NULL
.	NULL

In	NULL
parallel	NULL
footprint	NULL
experiments	NULL
,	NULL
factors	NULL
AP-1	NULL
,	NULL
AP-3	NULL
and	NULL
the	NULL
Octamer	NULL
factors	NULL
Oct-1	NULL
and	NULL
Oct-2A	NULL
bound	NULL
to	NULL
several	NULL
sites	NULL
of	NULL
the	NULL
I1-4	NULL
promoter	NULL
.	NULL

However	NULL
,	NULL
the	NULL
protection	NULL
over	NULL
these	NULL
sites	NULL
did	NULL
not	NULL
coincide	NULL
with	NULL
that	NULL
of	NULL
cellular	NULL
proteins	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
these	NULL
factors	NULL
bind	NULL
in	NULL
concert	NULL
with	NULL
other	NULL
factors	NULL
to	NULL
the	NULL
Il-4	NULL
promoter	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
this	NULL
appears	NULL
to	NULL
be	NULL
true	NULL
for	NULL
AP-1	NULL
which	NULL
appears	NULL
to	NULL
interact	NULL
with	NULL
other	NULL
factors	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
NFAT-1	NULL
,	NULL
the	NULL
most	NULL
prominent	NULL
purine	NULL
box	NULL
factor	NULL
(	NULL
32-34	NULL
)	NULL
,	NULL
and	NULL
for	NULL
the	NULL
Octamer	NULL
factors	NULL
which	NULL
,	NULL
along	NULL
with	NULL
NFAT-1	NULL
,	NULL
bind	NULL
to	NULL
several	NULL
of	NULL
II-4	NULL
purine	NULL
boxes	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
purine	NULL
boxes	NULL
of	NULL
the	NULL
Il-4	NULL
promoter	NULL
are	NULL
NFAT-1	NULL
binding	NULL
sites	NULL
In	NULL
order	NULL
to	NULL
test	NULL
whether	NULL
the	NULL
II-4	NULL
Pu-boxes	NULL
are	NULL
bound	NULL
by	NULL
NFAT-1	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
four	NULL
I1-4	NULL
Pu-boxes	NULL
with	NULL
those	NULL
binding	NULL
to	NULL
the	NULL
II-2	NULL
Pu-boxes	NULL
in	NULL
EMSAs	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
incubation	NULL
of	NULL
Pu-bs	NULL
(	NULL
II-4	NULL
)	NULL
and	NULL
Pu-b	NULL
;	NULL
,	NULL
(	NULL
II-2	NULL
)	NULL
probes	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
uninduced	NULL
El4	NULL
cells	NULL
or	NULL
from	NULL
cells	NULL
induced	NULL
for	NULL
4	NULL
h	NULL
by	NULL
TPA/ionomycin	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
CsA	NULL
,	NULL
resulted	NULL
in	NULL
very	NULL
similar	NULL
factor	NULL
complexes	NULL
.	NULL

The	NULL
most	NULL
prominent	NULL
complex	NULL
generated	NULL
with	NULL
both	NULL
probes	NULL
is	NULL
inducible	NULL
by	NULL
TPA/ConA	NULL
(	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
with	NULL
11	NULL
and	NULL
12	NULL
)	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
is	NULL
totally	NULL
suppressed	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
CsA	NULL
(	NULL
see	NULL
lanes	NULL
8	NULL
and	NULL
17	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
Pu-b4	NULL
,	NULL
and	NULL
Pu-b	NULL
;	NULL
DNAs	NULL
to	NULL
the	NULL
assays	NULL
competed	NULL
with	NULL
the	NULL
factor	NULL
binding	NULL
to	NULL
both	NULL
probes	NULL
(	NULL
see	NULL
lanes	NULL
3-5	NULL
and	NULL
13-15	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
same	NULL
excess	NULL
of	NULL
a	NULL
consensus	NULL
Octamer	NULL
site	NULL
(	NULL
Oct	NULL
;	NULL
lanes	NULL
7	NULL
,	NULL
9	NULL
and	NULL
18	NULL
)	NULL
or	NULL
an	NULL
Octamer	NULL
site	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
(	NULL
UPS	NULL
;	NULL
lanes	NULL
6	NULL
and	NULL
16	NULL
)	NULL
prevented	NULL
the	NULL
binding	NULL
of	NULL
Oct-like	NULL
factors	NULL
to	NULL
the	NULL
Pu-boxes	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
for	NULL
the	NULL
Pu-boxes	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
C	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
and	NULL
D	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
,	NULL
(	NULL
i	NULL
)	NULL
the	NULL
induction	NULL
of	NULL
factor	NULL
binding	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
its	NULL
inhibition	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
CsA	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
competition	NULL
of	NULL
factor	NULL
binding	NULL
by	NULL
each	NULL
Pu-box	NULL
probe	NULL
indicate	NULL
that	NULL
the	NULL
most	NULL
prominent	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
II-4	NULL
Pu-boxes	NULL
is	NULL
indistinguishable	NULL
from	NULL
NFAT-1	NULL
.	NULL

The	NULL
partial	NULL
competition	NULL
by	NULL
consensus	NULL
sequences	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
AP-1	NULL
and	NULL
Ets	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
which	NULL
have	NULL
binding	NULL
properties	NULL
in	NULL
common	NULL
with	NULL
NFAT-1	NULL
(	NULL
32-34	NULL
)	NULL
,	NULL
are	NULL
a	NULL
further	NULL
indication	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
NFAT-1	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
supported	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
since	NULL
mutation	NULL
of	NULL
two	NULL
G	NULL
residues	NULL
within	NULL
the	NULL
sequence	NULL
GGAAA	NULL
of	NULL
all	NULL
Pu-boxes	NULL
completely	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
NFAT-1	NULL
to	NULL
the	NULL
5700	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
ma	NULL
nÂ®	NULL
Figure	NULL
5	NULL
.	NULL

The	NULL
Octamer-like	NULL
sequence	NULL
ATGTAAAC	NULL
of	NULL
Pu-by	NULL
is	NULL
a	NULL
target	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
Octamer	NULL
factors	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Chimeric	NULL
GST-Oct-l	NULL
protein	NULL
binds	NULL
to	NULL
Pu-by	NULL
DNA	NULL
and	NULL
Pu-by-NM	NULL
DNAs	NULL
but	NULL
binds	NULL
only	NULL
poorly	NULL
to	NULL
a	NULL
Pu-by.qy	NULL
probe	NULL
containing	NULL
a	NULL
mutated	NULL
Octamer	NULL
motif	NULL
.	NULL

20	NULL
ng	NULL
GST-Oct-1	NULL
protein	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
Pu-by	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
,	NULL
Pu-bg.yy	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
or	NULL
Pu-bg	NULL
opy	NULL
probe	NULL
(	NULL
lanes	NULL
8-10	NULL
)	NULL
.	NULL

Note	NULL
the	NULL
weak	NULL
binding	NULL
of	NULL
chimeric	NULL
Octamer	NULL
protein	NULL
to	NULL
the	NULL
Pu-bg.qy	NULL
probe	NULL
with	NULL
the	NULL
mutated	NULL
Octamer	NULL
site	NULL
ATGTGGAC	NULL
.	NULL

In	NULL
lane	NULL
1	NULL
,	NULL
no	NULL
protein	NULL
was	NULL
added	NULL
to	NULL
the	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Mutation	NULL
of	NULL
Octamer	NULL
site	NULL
of	NULL
Pu-by	NULL
impairs	NULL
its	NULL
proto-enhancer	NULL
activity	NULL
.	NULL

The	NULL
constructs	NULL
3	NULL
X	NULL
Pu-bg	NULL
(	NULL
WT	NULL
)	NULL
and	NULL
Pu-by	NULL
oy	NULL
(	NULL
OM	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
murine	NULL
El4	NULL
T	NULL
lymphoma	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
inducible	NULL
activity	NULL
was	NULL
determined	NULL
upon	NULL
activation	NULL
of	NULL
cells	NULL
by	NULL
TPA/ionomycin	NULL
for	NULL
20	NULL
h.	NULL
Shown	NULL
are	NULL
the	NULL
mean	NULL
values	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
.	NULL

mutated	NULL
probe	NULL
Pu-bg	NULL
my	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
21-24	NULL
)	NULL
.	NULL

These	NULL
G	NULL
residues	NULL
have	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
contact	NULL
points	NULL
of	NULL
NFAT-1	NULL
(	NULL
31	NULL
,	NULL
33	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
test	NULL
which	NULL
members	NULL
of	NULL
AP-1	NULL
(	NULL
Jun/Fos	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
are	NULL
part	NULL
of	NULL
NFAT	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
I1-4	NULL
Pu-boxes	NULL
in	NULL
supershift	NULL
experiments	NULL
we	NULL
used	NULL
a	NULL
panel	NULL
of	NULL
antibodies	NULL
specific	NULL
for	NULL
all	NULL
the	NULL
known	NULL
members	NULL
of	NULL
Jun/Fos	NULL
factor	NULL
family	NULL
.	NULL

Using	NULL
a	NULL
TRE	NULL
consensus	NULL
site	NULL
and	NULL
nuclear	NULL
proteins	NULL
from	NULL
induced	NULL
El4	NULL
cells	NULL
,	NULL
the	NULL
incubation	NULL
with	NULL
Â«	NULL
-JunD	NULL
,	NULL
Â«	NULL
-c-Fos	NULL
,	NULL
Â«	NULL
-FosB	NULL
and	NULL
Fra-1	NULL
resulted	NULL
in	NULL
distinct	NULL
supershifts	NULL
.	NULL

No	NULL
supershifts	NULL
were	NULL
detected	NULL
with	NULL
-c-Jun	NULL
and	NULL
-Fra-2	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
using	NULL
a	NULL
Pu-by	NULL
probe	NULL
in	NULL
the	NULL
supershift	NULL
assays	NULL
,	NULL
~-Fra-2	NULL
gave	NULL
rise	NULL
to	NULL
the	NULL
most	NULL
prominent	NULL
supershift	NULL
,	NULL
and	NULL
a	NULL
weak	NULL
reaction	NULL
was	NULL
also	NULL
observed	NULL
for	NULL
Â«	NULL
-JunB	NULL
(	NULL
which	NULL
can	NULL
hardly	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
but	NULL
in	NULL
the	NULL
original	NULL
autoradiographs	NULL
)	NULL
.	NULL

Since	NULL
identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
a	NULL
Pu-b	NULL
,	NULL
probe	NULL
of	NULL
II-2	NULL
promoter	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
Fra-2	NULL
(	NULL
and	NULL
JunB	NULL
)	NULL
proteins	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
most	NULL
prevalent	NULL
AP-1	NULL
components	NULL
of	NULL
NFAT	NULL
in	NULL
E14	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

Three	NULL
of	NULL
four	NULL
purine	NULL
boxes	NULL
are	NULL
also	NULL
weak	NULL
binding	NULL
sites	NULL
for	NULL
octamer	NULL
factors	NULL
EMSAs	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
induced	NULL
and	NULL
CsA-treated	NULL
El4	NULL
cells	NULL
with	NULL
the	NULL
Pu-boxes	NULL
B	NULL
,	NULL
C	NULL
and	NULL
D	NULL
revealed	NULL
the	NULL
weak	NULL
binding	NULL
of	NULL
Octamer	NULL
factors	NULL
to	NULL
these	NULL
sites	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
Octamer-like	NULL
complexes	NULL
appear	NULL
to	NULL
be	NULL
formed	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
ubiquitous	NULL
factor	NULL
Oct-1	NULL
and	NULL
the	NULL
lymphoid-specific	NULL
factors	NULL
Oct-2A	NULL
and	NULL
Oct-2B	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
since	NULL
(	NULL
i	NULL
)	NULL
they	NULL
show	NULL
the	NULL
same	NULL
electrophoretic	NULL
mobility	NULL
as	NULL
complexes	NULL
generated	NULL
by	NULL
the	NULL
incubation	NULL
of	NULL
an	NULL
Octamer	NULL
binding	NULL
site	NULL
(	NULL
such	NULL
as	NULL
the	NULL
UPS	NULL
motif	NULL
of	NULL
the	NULL
II-2	NULL
enhancer	NULL
:	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
25	NULL
)	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
their	NULL
generation	NULL
was	NULL
specifically	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
genuine	NULL
Octamer	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
suppressed	NULL
in	NULL
pre-incubations	NULL
with	NULL
antibodies	NULL
raised	NULL
against	NULL
Vaccinia-expressed	NULL
Oct-2A	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
chimeric	NULL
recombinant	NULL
GST-Oct-1	NULL
and	NULL
GST-Oct-2A	NULL
proteins	NULL
to	NULL
Pu-by	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
and	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

All	NULL
three	NULL
Pu-boxes	NULL
contain	NULL
Octamer	NULL
like	NULL
120	NULL
A.	NULL
z	NULL
1001	NULL
OQ	NULL
c	NULL
Â«	NULL
w-	NULL
E	NULL
ti	NULL
B	NULL
TiiCsA	NULL
=	NULL
-	NULL
801	NULL
B	NULL
5	NULL
<	NULL
4	NULL
i-	NULL
601	NULL
<	NULL
O	NULL
0	NULL
40	NULL
7	NULL
F	NULL
I	NULL
6	NULL
a	NULL
201	NULL
114-270	NULL
1L4-270	NULL
(	NULL
4M	NULL
)	NULL
Pu-bayg	NULL
Pu-bgyy	NULL
Pubopy	NULL
Pubpy	NULL
100	NULL
B.	NULL
O	NULL
c	NULL
~	NULL
E	NULL
t	NULL
s	NULL
=	NULL
so	NULL
N	NULL
tiicsa	NULL
3	NULL
H	NULL
E14	NULL
Jurkat	NULL
3	NULL
&	NULL
so	NULL
3	NULL
ao	NULL
49	NULL
]	NULL
&	NULL
o	NULL
<	NULL
o	NULL
201	NULL
<	NULL
4	NULL
O	NULL
o-3xPu-bA	NULL
-	NULL
3xPu-bB	NULL
4xPu-bd	NULL
3xPu-bB	NULL
4xPu-bd	NULL
Figure	NULL
6	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
I1-4	NULL
promoter/enhancer	NULL
in	NULL
El4	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Mutations	NULL
within	NULL
the	NULL
purine	NULL
boxes	NULL
diminish	NULL
the	NULL
I1-4	NULL
promoter	NULL
activity	NULL
.	NULL

15	NULL
ug	NULL
DNA	NULL
of	NULL
the	NULL
CAT	NULL
constructs	NULL
1L4-270	NULL
,	NULL
1L4-270	NULL
(	NULL
Pu-bay	NULL
)	NULL
,	NULL
IL4-270	NULL
(	NULL
Pu-bgy	NULL
)	NULL
,	NULL
1L4-270	NULL
(	NULL
Pu-bcy	NULL
)	NULL
,	NULL
IL4-270	NULL
(	NULL
Pu-bpy	NULL
)	NULL
and	NULL
IL4-270	NULL
(	NULL
4M	NULL
)	NULL
containing	NULL
the	NULL
wild-type	NULL
II-4	NULL
promoter	NULL
or	NULL
the	NULL
promoter	NULL
with	NULL
mutations	NULL
in	NULL
single	NULL
purine	NULL
boxes	NULL
or	NULL
in	NULL
all	NULL
four	NULL
boxes	NULL
were	NULL
transfected	NULL
into	NULL
El4	NULL
cells	NULL
.	NULL

20	NULL
h	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
divided	NULL
.	NULL

One	NULL
third	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
left	NULL
as	NULL
uninduced	NULL
control	NULL
(	NULL
C	NULL
)	NULL
,	NULL
one	NULL
induced	NULL
by	NULL
TPA/ionomycin	NULL
(	NULL
10	NULL
ng/ml	NULL
,	NULL
0.5	NULL
aM	NULL
)	NULL
(	NULL
T/T	NULL
)	NULL
or	NULL
induced	NULL
and	NULL
treated	NULL
by	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
(	NULL
T/A+CsA	NULL
)	NULL
.	NULL

20	NULL
h	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
CAT	NULL
assays	NULL
were	NULL
done	NULL
.	NULL

The	NULL
mean	NULL
values	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
I1-4	NULL
Pu-boxes	NULL
Pu-b4	NULL
,	NULL
and	NULL
Pu-by	NULL
act	NULL
as	NULL
inducible	NULL
proto-enhancer	NULL
elements	NULL
in	NULL
El4	NULL
T	NULL
cells	NULL
.	NULL

15	NULL
ug	NULL
DNA	NULL
of	NULL
constructs	NULL
3x	NULL
Pu-b4	NULL
,	NULL
3x	NULL
Pu-by	NULL
and	NULL
4x	NULL
Pu-by	NULL
containing	NULL
three	NULL
or	NULL
four	NULL
copies	NULL
of	NULL
corresponding	NULL
Pu-boxes	NULL
from	NULL
the	NULL
I1-4	NULL
(	NULL
Pu-b4	NULL
,	NULL
and	NULL
)	NULL
or	NULL
1-2	NULL
promoters	NULL
(	NULL
Pu-b	NULL
,	NULL
)	NULL
were	NULL
transfected	NULL
either	NULL
into	NULL
El4	NULL
T	NULL
cells	NULL
or	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
only	NULL
3x	NULL
Pu-by	NULL
and	NULL
4x	NULL
Pu-by4	NULL
)	NULL
.	NULL

20	NULL
h	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
divided	NULL
and	NULL
treated	NULL
with	NULL
TPA/ionomycin	NULL
(	NULL
T/D	NULL
,	NULL
with	NULL
T/I	NULL
and	NULL
CsA	NULL
(	NULL
T/I+CsA	NULL
)	NULL
or	NULL
left	NULL
as	NULL
uninduced	NULL
control	NULL
.	NULL

The	NULL
mean	NULL
values	NULL
of	NULL
three	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

sequences	NULL
adjacent	NULL
to	NULL
their	NULL
GGAAA	NULL
motifs	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
and	NULL
B	NULL
)	NULL
which	NULL
might	NULL
be	NULL
the	NULL
target	NULL
of	NULL
Octamer	NULL
factors	NULL
.	NULL

This	NULL
was	NULL
proven	NULL
for	NULL
the	NULL
Pu-boxs	NULL
since	NULL
conversion	NULL
of	NULL
the	NULL
underlined	NULL
A	NULL
residues	NULL
in	NULL
the	NULL
Octamer	NULL
like	NULL
sequence	NULL
ATGTAAAC	NULL
to	NULL
G	NULL
residues	NULL
markedly	NULL
diminished	NULL
the	NULL
binding	NULL
of	NULL
chimeric	NULL
GST-Oct-1	NULL
protein	NULL
to	NULL
the	NULL
Pu-bg.oy	NULL
,	NULL
probe	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
NFAT-1	NULL
binding	NULL
sequence	NULL
GGAAA	NULL
(	NULL
in	NULL
the	NULL
Pu-bg	NULL
yy	NULL
probe	NULL
)	NULL
was	NULL
without	NULL
effect	NULL
on	NULL
the	NULL
Octamer	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
5-10	NULL
)	NULL
.	NULL

The	NULL
Pu-by	NULL
and	NULL
Pu-by	NULL
sequences	NULL
also	NULL
contain	NULL
TAAT	NULL
motifs	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
which	NULL
correspond	NULL
to	NULL
binding	NULL
sites	NULL
of	NULL
homeodomain	NULL
proteins	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
NFAT	NULL
and	NULL
octamer	NULL
factors	NULL
to	NULL
the	NULL
II-4	NULL
Pu-boxes	NULL
contributes	NULL
to	NULL
the	NULL
I1-4	NULL
promoter	NULL
activity	NULL
The	NULL
binding	NULL
of	NULL
NFAT	NULL
to	NULL
the	NULL
purine	NULL
boxes	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
in	NULL
E14	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
5701	NULL
A	NULL
.	NULL

B.	NULL
Proteins	NULL
|-	NULL
HMGI	NULL
(	NULL
Y	NULL
)	NULL
--	NULL
-	NULL
Tcells	NULL
gp	NULL
1.2	NULL
#	NULL
$	NULL
0	NULL
%	NULL
005	NULL
0	NULL
%	NULL
Probe	NULL
BoxlIâ~-â*-TCEP_	NULL
â	NULL
{	NULL
Â§	NULL
}	NULL
Â§E	NULL
'	NULL
g	NULL
te	NULL
Q	NULL
a	NULL
<	NULL
o	NULL
=	NULL
<	NULL
2,2	NULL
=	NULL
Â«	NULL
g	NULL
``	NULL
~*	NULL
*	NULL
come	NULL
*	NULL
i	NULL
*	NULL
oe	NULL
0	NULL
0	NULL
0	NULL
8	NULL
'	NULL
o	NULL
t	NULL
*	NULL
,	NULL
HMG	NULL
I	NULL
(	NULL
V	NULL
)	NULL
wfe	NULL
_	NULL
.	NULL

4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
91011121314	NULL
15	NULL
16	NULL
17	NULL
18	NULL
acetylation	NULL
)	NULL
y	NULL
(	NULL
%	NULL
activit	NULL
Figure	NULL
7	NULL
.	NULL

Box	NULL
II	NULL
of	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
binding	NULL
site	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
protein	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSAs	NULL
.	NULL

Detection	NULL
of	NULL
binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
to	NULL
box	NULL
II	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

Box	NULL
II	NULL
(	NULL
lanes	NULL
1-10	NULL
)	NULL
,	NULL
TCEp	NULL
(	NULL
lanes	NULL
11-14	NULL
)	NULL
,	NULL
Adenovirus	NULL
major	NULL
late	NULL
TATA	NULL
box	NULL
(	NULL
lane	NULL
15	NULL
)	NULL
,	NULL
TCEd	NULL
(	NULL
lane	NULL
16	NULL
)	NULL
,	NULL
Pu-by	NULL
(	NULL
lane	NULL
17	NULL
)	NULL
or	NULL
probes	NULL
(	NULL
lane	NULL
18	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
isolated	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
protein	NULL
(	NULL
lanes	NULL
1-5	NULL
)	NULL
or	NULL
nuclear	NULL
proteins	NULL
from	NULL
human	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
induced	NULL
for	NULL
15	NULL
h	NULL
by	NULL
TPA/ionomycin	NULL
(	NULL
lanes	NULL
6-18	NULL
)	NULL
.	NULL

Since	NULL
HMG	NULL
proteins	NULL
interact	NULL
with	NULL
the	NULL
minor	NULL
groove	NULL
of	NULL
DNA	NULL
,	NULL
poly	NULL
dG-dC	NULL
was	NULL
added	NULL
as	NULL
unspecific	NULL
competitor	NULL
(	NULL
in	NULL
lanes	NULL
6-18	NULL
;	NULL
1	NULL
ug	NULL
per	NULL
assay	NULL
)	NULL
.	NULL

For	NULL
specific	NULL
competition	NULL
,	NULL
50	NULL
ng	NULL
of	NULL
the	NULL
following	NULL
oligonucleotides	NULL
were	NULL
added	NULL
:	NULL
lanes	NULL
2	NULL
,	NULL
7	NULL
and	NULL
12	NULL
,	NULL
box	NULL
II	NULL
,	NULL
lanes	NULL
3,8	NULL
and	NULL
13	NULL
,	NULL
the	NULL
TATA	NULL
box	NULL
of	NULL
Adenovirus	NULL
major	NULL
late	NULL
promoter	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
,	NULL
TCEp	NULL
;	NULL
lanes	NULL
5	NULL
,	NULL
10	NULL
and	NULL
14	NULL
,	NULL
TREp	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
and	NULL
(	NULL
C	NULL
)	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
overexpression	NULL
suppresses	NULL
the	NULL
inducible	NULL
activity	NULL
of	NULL
1-4	NULL
promoter	NULL
in	NULL
El4	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
One	NULL
typical	NULL
CAT	NULL
transfection	NULL
experiment	NULL
.	NULL

2	NULL
ug	NULL
of	NULL
II-4	NULL
promoter	NULL
CAT	NULL
construct	NULL
IL4-270	NULL
was	NULL
co-transfected	NULL
with	NULL
the	NULL
empty	NULL
pSG	NULL
vector	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
the	NULL
HMG	NULL
expression	NULL
(	NULL
sense	NULL
)	NULL
vector	NULL
pSG-HMGY	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
or	NULL
the	NULL
antisense	NULL
vector	NULL
pSG-YGMH	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
into	NULL
El4	NULL
cells	NULL
.	NULL

20	NULL
h	NULL
upon	NULL
induction	NULL
by	NULL
TPA/ionomycin	NULL
,	NULL
CAT	NULL
assays	NULL
were	NULL
done	NULL
using	NULL
the	NULL
lysates	NULL
from	NULL
uninduced	NULL
(	NULL
no	NULL
.	NULL

1	NULL
,	NULL
3	NULL
and	NULL
5	NULL
)	NULL
and	NULL
induced	NULL
cells	NULL
(	NULL
no	NULL
.	NULL

2	NULL
,	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
mean	NULL
CAT	NULL
values	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
.	NULL

This	NULL
can	NULL
be	NULL
concluded	NULL
from	NULL
the	NULL
introduction	NULL
of	NULL
point	NULL
mutations	NULL
into	NULL
all	NULL
four	NULL
purine	NULL
boxes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
for	NULL
the	NULL
construct	NULL
IL4-270	NULL
(	NULL
4M	NULL
)	NULL
,	NULL
when	NULL
the	NULL
GGAAA	NULL
sequences	NULL
of	NULL
all	NULL
four	NULL
purine	NULL
boxes	NULL
were	NULL
mutated	NULL
,	NULL
the	NULL
promoter	NULL
activity	NULL
was	NULL
completely	NULL
abolished	NULL
.	NULL

Mutating	NULL
one	NULL
of	NULL
four	NULL
purine	NULL
boxes	NULL
resulted	NULL
in	NULL
quite	NULL
different	NULL
effects	NULL
on	NULL
the	NULL
promoter	NULL
activity	NULL
.	NULL

Whereas	NULL
the	NULL
mutations	NULL
in	NULL
Pu-bp	NULL
and	NULL
,	NULL
albeit	NULL
less	NULL
dramatic	NULL
,	NULL
Pu-by	NULL
and	NULL
Pu-b	NULL
;	NULL
had	NULL
strong	NULL
inhibitory	NULL
effects	NULL
on	NULL
the	NULL
promoter	NULL
activity	NULL
,	NULL
the	NULL
mutation	NULL
of	NULL
Pu-ba	NULL
led	NULL
only	NULL
to	NULL
a	NULL
moderate	NULL
decrease	NULL
of	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

While	NULL
these	NULL
results	NULL
demonstrate	NULL
the	NULL
importance	NULL
of	NULL
NFAT	NULL
binding	NULL
in	NULL
the	NULL
inducible	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
,	NULL
they	NULL
also	NULL
suggest	NULL
that	NULL
the	NULL
four	NULL
purine	NULL
boxes	NULL
correspond	NULL
to	NULL
individual	NULL
promoter	NULL
elements	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
the	NULL
activity	NULL
of	NULL
single	NULL
purine	NULL
boxes	NULL
in	NULL
more	NULL
detail	NULL
we	NULL
constructed	NULL
CAT	NULL
plasmids	NULL
bearing	NULL
multiple	NULL
copies	NULL
of	NULL
Pu-b	NULL
,	NULL
or	NULL
Pu-bg	NULL
.	NULL

When	NULL
cloned	NULL
in	NULL
three	NULL
copies	NULL
,	NULL
both	NULL
Pu-boxes	NULL
acted	NULL
as	NULL
inducible	NULL
proto-enhancers	NULL
after	NULL
tranfection	NULL
into	NULL
El4	NULL
cells	NULL
,	NULL
and	NULL
CsA	NULL
interfered	NULL
with	NULL
their	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Pu-by	NULL
on	NULL
CAT	NULL
induction	NULL
was	NULL
about	NULL
threefold	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
Pu-b	NULL
,	NULL
and	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
Pu-b	NULL
;	NULL
,	NULL
from	NULL
the	NULL
II-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

When	NULL
the	NULL
activity	NULL
of	NULL
Pu-bye	NULL
was	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
Pu-b	NULL
;	NULL
in	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
surprisingly	NULL
the	NULL
Pu-by	NULL
construct	NULL
was	NULL
completely	NULL
inactive	NULL
whereas	NULL
the	NULL
Pu-b4	NULL
construct	NULL
remained	NULL
as	NULL
active	NULL
as	NULL
in	NULL
El4	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Since	NULL
Jurkat	NULL
cells	NULL
lack	NULL
measurable	NULL
amounts	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
factor	NULL
Oct-2	NULL
,	NULL
which	NULL
is	NULL
constitutively	NULL
synthesized	NULL
in	NULL
El4	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
21	NULL
)	NULL
,	NULL
one	NULL
may	NULL
assume	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
Octamer	NULL
factors	NULL
,	NULL
in	NULL
particular	NULL
of	NULL
Oct-2	NULL
,	NULL
to	NULL
Pu-by	NULL
is	NULL
important	NULL
for	NULL
the	NULL
function	NULL
of	NULL
the	NULL
element	NULL
.	NULL

This	NULL
conclusion	NULL
finds	NULL
support	NULL
in	NULL
the	NULL
weak	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
construct	NULL
3	NULL
XPu-bg	NULL
oy	NULL
which	NULL
carries	NULL
three	NULL
copies	NULL
of	NULL
Pu-bg	NULL
;	NULL
with	NULL
mutations	NULL
in	NULL
its	NULL
Octamer	NULL
sequence	NULL
.	NULL

In	NULL
El4	NULL
cells	NULL
,	NULL
this	NULL
construct	NULL
showed	NULL
only	NULL
one	NULL
fourth	NULL
of	NULL
activity	NULL
of	NULL
the	NULL
3	NULL
X	NULL
Pu-by	NULL
wild-type	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
suppresses	NULL
the	NULL
II-4	NULL
promoter	NULL
activity	NULL
Box	NULL
II	NULL
(	NULL
located	NULL
around	NULL
position	NULL
-200	NULL
,	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
is	NULL
the	NULL
only	NULL
promoter	NULL
site	NULL
which	NULL
was	NULL
bound	NULL
by	NULL
proteins	NULL
isolated	NULL
by	NULL
affinity	NULL
chromatography	NULL
on	NULL
a	NULL
TCEp	NULL
DNA	NULL
column	NULL
in	NULL
DNase	NULL
footprint	NULL
protection	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
TCEp	NULL
(	NULL
'proximal	NULL
T	NULL
cell	NULL
element	NULL
'	NULL
)	NULL
is	NULL
a	NULL
protein	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
which	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
other	NULL
sites	NULL
,	NULL
did	NULL
not	NULL
show	NULL
any	NULL
proto-enhancer	NULL
activity	NULL
when	NULL
it	NULL
was	NULL
cloned	NULL
in	NULL
multiple	NULL
copies	NULL
in	NULL
front	NULL
of	NULL
a	NULL
test	NULL
gene	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Box	NULL
II	NULL
and	NULL
the	NULL
TCEp	NULL
span	NULL
a	NULL
common	NULL
DNA	NULL
stretch	NULL
of	NULL
six	NULL
AT	NULL
base	NULL
pairs	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
which	NULL
,	NULL
therefore	NULL
,	NULL
corresponds	NULL
to	NULL
a	NULL
binding	NULL
site	NULL
of	NULL
high	NULL
mobility	NULL
group	NULL
(	NULL
HMG	NULL
)	NULL
protein	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
EMSAs	NULL
using	NULL
nuclear	NULL
proteins	NULL
from	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
,	NULL
the	NULL
generation	NULL
of	NULL
one	NULL
prominent	NULL
factor	NULL
complex	NULL
was	NULL
observed	NULL
after	NULL
incubation	NULL
with	NULL
box	NULL
II	NULL
and	NULL
TCEp	NULL
probes	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
11	NULL
)	NULL
.	NULL

The	NULL
formation	NULL
of	NULL
this	NULL
rapidly	NULL
migrating	NULL
complex	NULL
could	NULL
be	NULL
competed	NULL
by	NULL
a	NULL
100	NULL
fold	NULL
molar	NULL
excess	NULL
of	NULL
homologous	NULL
probes	NULL
or	NULL
the	NULL
TATA	NULL
box	NULL
of	NULL
Adenovirus	NULL
major	NULL
late	NULL
promoter	NULL
(	NULL
a	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
site	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
the	NULL
same	NULL
excess	NULL
of	NULL
the	NULL
TREp	NULL
,	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
showed	NULL
the	NULL
same	NULL
5702	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
Figure	NULL
8	NULL
.	NULL

Scheme	NULL
of	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
murine	NULL
II-4	NULL
promoter/enhancer	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Compilation	NULL
of	NULL
results	NULL
of	NULL
DNAse	NULL
I	NULL
footprint	NULL
protection	NULL
and	NULL
EMSA	NULL
experiments	NULL
.	NULL

Solid	NULL
brackets	NULL
indicate	NULL
the	NULL
protection	NULL
by	NULL
DNA	NULL
binding	NULL
proteins	NULL
in	NULL
protein	NULL
extracts	NULL
from	NULL
El4	NULL
T	NULL
lymphoma	NULL
cells	NULL
and	NULL
P815	NULL
mastocytoma	NULL
cells	NULL
,	NULL
the	NULL
interrupted	NULL
brackets	NULL
indicate	NULL
the	NULL
protection	NULL
by	NULL
proteins	NULL
from	NULL
HeLa	NULL
cells	NULL
.	NULL

The	NULL
Ets-like	NULL
'core	NULL
'	NULL
of	NULL
NFAT-1	NULL
binding	NULL
motifs	NULL
,	NULL
the	NULL
Oct	NULL
like	NULL
binding	NULL
motifs	NULL
and	NULL
TAAT	NULL
sequences	NULL
corresponding	NULL
to	NULL
binding	NULL
sites	NULL
of	NULL
homeobox	NULL
proteins	NULL
(	NULL
35	NULL
)	NULL
are	NULL
indicated	NULL
by	NULL
stippled	NULL
boxes	NULL
.	NULL

The	NULL
orientation	NULL
of	NULL
NFAT-1	NULL
and	NULL
Oct	NULL
like	NULL
sequences	NULL
is	NULL
indicated	NULL
by	NULL
horizontal	NULL
arrows	NULL
.	NULL

The	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
motif	NULL
of	NULL
box	NULL
II	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
hatched	NULL
box	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
promoter/enhancer	NULL
DNA	NULL
is	NULL
from	NULL
Otsuka	NULL
et	NULL
al	NULL
.	NULL

(	NULL
9	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Sequence	NULL
homologies	NULL
between	NULL
protein	NULL
binding	NULL
sites	NULL
of	NULL
I1-4	NULL
and	NULL
11-2	NULL
promoter/enhancers	NULL
.	NULL

The	NULL
common	NULL
GGAAA	NULL
motif	NULL
of	NULL
purine	NULL
boxes	NULL
and	NULL
the	NULL
HMG	NULL
binding	NULL
motif	NULL
within	NULL
box	NULL
II	NULL
and	NULL
TCEp	NULL
are	NULL
boxed	NULL
.	NULL

The	NULL
Octamer	NULL
like	NULL
motifs	NULL
are	NULL
underlined	NULL
.	NULL

electrophoretic	NULL
mobility	NULL
and	NULL
DNA	NULL
binding	NULL
behaviour	NULL
as	NULL
a	NULL
complex	NULL
which	NULL
was	NULL
formed	NULL
after	NULL
incubation	NULL
with	NULL
purified	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
isolated	NULL
from	NULL
murine	NULL
Ehrlich	NULL
ascites	NULL
tumor	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

This	NULL
demonstrates	NULL
that	NULL
both	NULL
box	NULL
II	NULL
of	NULL
the	NULL
I1-4	NULL
promoter	NULL
and	NULL
the	NULL
TCEp	NULL
of	NULL
the	NULL
I1-2	NULL
promoter	NULL
are	NULL
binding	NULL
sites	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

There	NULL
are	NULL
,	NULL
however	NULL
,	NULL
more	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
within	NULL
the	NULL
I1-4	NULL
promoter	NULL
than	NULL
box	NULL
II	NULL
.	NULL

Among	NULL
them	NULL
are	NULL
the	NULL
purine	NULL
boxes	NULL
Pu-bp	NULL
and	NULL
Pu-be	NULL
which	NULL
carry	NULL
stretches	NULL
of	NULL
12	NULL
and	NULL
8	NULL
AT	NULL
residues	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
elucidate	NULL
whether	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
II-4	NULL
promoter	NULL
activity	NULL
we	NULL
co-transfected	NULL
expression	NULL
vectors	NULL
containing	NULL
the	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
cDNA	NULL
in	NULL
the	NULL
sense	NULL
or	NULL
anti-sense	NULL
orientation	NULL
with	NULL
the	NULL
II-4	NULL
promoter	NULL
CAT	NULL
construct	NULL
IL4-270	NULL
into	NULL
E4	NULL
cells	NULL
.	NULL

The	NULL
overexpression	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
exerted	NULL
a	NULL
distinct	NULL
suppressive	NULL
effect	NULL
on	NULL
the	NULL
II-4	NULL
promoter	NULL
activity	NULL
whereas	NULL
the	NULL
opposite	NULL
effect	NULL
was	NULL
observed	NULL
for	NULL
the	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
antisense	NULL
construct	NULL
(	NULL
Figs	NULL
.	NULL

7B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
proteins	NULL
are	NULL
able	NULL
to	NULL
suppress	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
in	NULL
El4	NULL
cells	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
supported	NULL
by	NULL
an	NULL
increase	NULL
of	NULL
activity	NULL
of	NULL
CAT	NULL
constructs	NULL
which	NULL
carry	NULL
an	NULL
II-4	NULL
promoter	NULL
with	NULL
three	NULL
G	NULL
mutations	NULL
within	NULL
the	NULL
stretch	NULL
of	NULL
14	NULL
AT	NULL
residues	NULL
of	NULL
box	NULL
II	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
Fig	NULL
.	NULL

8	NULL
for	NULL
the	NULL
sequence	NULL
)	NULL
(	NULL
transfection	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
,	NULL
i.e	NULL
.	NULL

(	NULL
i	NULL
)	NULL
the	NULL
high	NULL
concentration	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
decrease	NULL
of	NULL
II-4	NULL
promoter	NULL
activity	NULL
as	NULL
a	NULL
result	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
overexpression	NULL
,	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
increase	NULL
of	NULL
II-4	NULL
promoter	NULL
activity	NULL
by	NULL
mutating	NULL
its	NULL
most	NULL
prominent	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
site	NULL
demonstrates	NULL
that	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
repression	NULL
of	NULL
Il-4	NULL
transcription	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
activity	NULL
of	NULL
and	NULL
the	NULL
protein	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
murine	NULL
1-4	NULL
promoter	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
the	NULL
immediate	NULL
upstream	NULL
DNA	NULL
segment	NULL
from	NULL
position	NULL
-12	NULL
to	NULL
-270	NULL
of	NULL
the	NULL
murine	NULL
1-4	NULL
gene	NULL
harbors	NULL
a	NULL
strong	NULL
inducible	NULL
and	NULL
cell	NULL
type-specific	NULL
enhancer	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
can	NULL
be	NULL
efficiently	NULL
induced	NULL
by	NULL
agents	NULL
which	NULL
activate	NULL
T	NULL
cells	NULL
,	NULL
its	NULL
induction	NULL
is	NULL
suppressed	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
CsA	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
inducible	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
see	NULL
Figs	NULL
.	NULL

1B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
II-4	NULL
promoter/enhancer	NULL
shares	NULL
several	NULL
properties	NULL
with	NULL
the	NULL
1-2	NULL
promoter/enhancer	NULL
,	NULL
and	NULL
several	NULL
factors	NULL
which	NULL
control	NULL
the	NULL
I1-2	NULL
promoter	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
I1-4	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
are	NULL
NFAT-1	NULL
and	NULL
Octamer	NULL
factors	NULL
and	NULL
,	NULL
as	NULL
we	NULL
show	NULL
here	NULL
for	NULL
the	NULL
first	NULL
time	NULL
,	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

There	NULL
are	NULL
four	NULL
NFAT-1	NULL
binding	NULL
sites	NULL
within	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
NFAT	NULL
to	NULL
these	NULL
sites	NULL
,	NULL
the	NULL
purine	NULL
boxes	NULL
,	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
promoter	NULL
activity	NULL
since	NULL
the	NULL
suppression	NULL
of	NULL
NFAT	NULL
-1	NULL
binding	NULL
by	NULL
mutating	NULL
the	NULL
purine	NULL
boxes	NULL
abolished	NULL
the	NULL
promoter	NULL
activity	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
negative	NULL
effect	NULL
of	NULL
the	NULL
immmunosuppressant	NULL
CsA	NULL
might	NULL
also	NULL
be	NULL
mediated	NULL
through	NULL
the	NULL
NFAT-1	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

NFAT-1	NULL
has	NULL
originally	NULL
been	NULL
described	NULL
as	NULL
a	NULL
T	NULL
cell-specific	NULL
I1-2	NULL
promoter	NULL
factor	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
which	NULL
is	NULL
stimulated	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
suppressed	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
CsA	NULL
(	NULL
22	NULL
,	NULL
31	NULL
,	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

NFAT-1	NULL
appears	NULL
to	NULL
consist	NULL
of	NULL
(	NULL
at	NULL
least	NULL
)	NULL
two	NULL
components	NULL
;	NULL
one	NULL
nuclear	NULL
AP-1	NULL
like	NULL
component	NULL
and	NULL
one	NULL
cytoplasmic	NULL
component	NULL
(	NULL
32	NULL
,	NULL
39	NULL
)	NULL
.	NULL

For	NULL
El4	NULL
T	NULL
lymphoma	NULL
cells	NULL
we	NULL
show	NULL
here	NULL
that	NULL
Fra-2	NULL
is	NULL
the	NULL
most	NULL
prominent	NULL
AP-1	NULL
like	NULL
component	NULL
of	NULL
NFAT-1	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NFAT	NULL
is	NULL
controlled	NULL
by	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
which	NULL
is	NULL
specifically	NULL
bound	NULL
and	NULL
inhibited	NULL
by	NULL
complexes	NULL
consisting	NULL
of	NULL
CsA	NULL
and	NULL
cyclophilin	NULL
(	NULL
or	NULL
FK506	NULL
and	NULL
FKBP	NULL
)	NULL
(	NULL
40-42	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
,	NULL
and	NULL
those	NULL
of	NULL
others	NULL
(	NULL
43	NULL
)	NULL
,	NULL
demonstrate	NULL
that	NULL
NFAT-1	NULL
is	NULL
not	NULL
only	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
1-2	NULL
promoter	NULL
but	NULL
also	NULL
in	NULL
that	NULL
of	NULL
other	NULL
lymphokine	NULL
genes	NULL
.	NULL

Contrary	NULL
to	NULL
its	NULL
original	NULL
designation	NULL
(	NULL
37	NULL
)	NULL
,	NULL
NFAT-1	NULL
occurs	NULL
also	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
22	NULL
)	NULL
and	NULL
,	NULL
as	NULL
shown	NULL
here	NULL
,	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

Three	NULL
of	NULL
four	NULL
NFAT-1	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
Il-4	NULL
promoter	NULL
are	NULL
linked	NULL
to	NULL
non-canonical	NULL
Octamer	NULL
sites	NULL
.	NULL

Although	NULL
in	NULL
some	NULL
of	NULL
the	NULL
EMSAs	NULL
Octamer	NULL
factors	NULL
were	NULL
also	NULL
found	NULL
to	NULL
bind	NULL
very	NULL
weakly	NULL
to	NULL
the	NULL
Pu-b	NULL
,	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
,	NULL
the	NULL
binding	NULL
affinities	NULL
of	NULL
Octamer	NULL
factors	NULL
to	NULL
the	NULL
I1-4	NULL
purine	NULL
boxes	NULL
B	NULL
,	NULL
C	NULL
and	NULL
D	NULL
are	NULL
stronger	NULL
than	NULL
to	NULL
the	NULL
1-2	NULL
purine	NULL
boxes	NULL
.	NULL

The	NULL
binding	NULL
affinities	NULL
are	NULL
,	NULL
however	NULL
,	NULL
at	NULL
least	NULL
5-10	NULL
fold	NULL
weaker	NULL
than	NULL
to	NULL
the	NULL
UPS	NULL
motif	NULL
of	NULL
the	NULL
N-2	NULL
promoter	NULL
or	NULL
to	NULL
a	NULL
consensus	NULL
Octamer	NULL
site	NULL
.	NULL

What	NULL
might	NULL
be	NULL
the	NULL
function	NULL
of	NULL
weak	NULL
binding	NULL
of	NULL
Octamer	NULL
factors	NULL
to	NULL
the	NULL
II-4	NULL
purine	NULL
boxes	NULL
?	NULL

In	NULL
transient	NULL
transfections	NULL
using	NULL
E14	NULL
cells	NULL
the	NULL
Pu-bp	NULL
behaved	NULL
like	NULL
the	NULL
Pu-by4	NULL
of	NULL
the	NULL
1-2	NULL
promoter	NULL
and	NULL
differed	NULL
in	NULL
its	NULL
induction	NULL
kinetics	NULL
from	NULL
the	NULL
UPS	NULL
motif	NULL
which	NULL
is	NULL
bound	NULL
by	NULL
Octamer	NULL
and	NULL
AP-1	NULL
like	NULL
factors	NULL
(	NULL
25	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
lack	NULL
Oct-2	NULL
,	NULL
the	NULL
Pu-by	NULL
was	NULL
uninducible	NULL
whereas	NULL
the	NULL
Pu-b4	NULL
was	NULL
strongly	NULL
induced	NULL
upon	NULL
TPA/ionomycin	NULL
treatment	NULL
.	NULL

These	NULL
results	NULL
and	NULL
the	NULL
weak	NULL
activity	NULL
of	NULL
the	NULL
construct	NULL
3	NULL
XPu-bg	NULL
oy	NULL
containing	NULL
mutated	NULL
Octamer	NULL
sites	NULL
demonstrate	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
NFAT-1	NULL
,	NULL
Octamer	NULL
factors	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
Pu-bs	NULL
activity	NULL
.	NULL

Oct-2	NULL
is	NULL
a	NULL
strong	NULL
transactivator	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
and	NULL
inducible	NULL
in	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
,	NULL
and	NULL
one	NULL
may	NULL
assume	NULL
that	NULL
it	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
II-4	NULL
induction	NULL
.	NULL

The	NULL
low	NULL
binding	NULL
affinity	NULL
of	NULL
Octamer	NULL
factors	NULL
to	NULL
the	NULL
II-4	NULL
purine	NULL
boxes	NULL
might	NULL
indicate	NULL
that	NULL
higher	NULL
Oct-2	NULL
concentrations	NULL
are	NULL
necessary	NULL
to	NULL
transactivate	NULL
the	NULL
I1-4	NULL
gene	NULL
than	NULL
the	NULL
II-2	NULL
gene	NULL
which	NULL
harbors	NULL
at	NULL
least	NULL
one	NULL
high	NULL
affinity	NULL
Octamer	NULL
sites	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
here	NULL
that	NULL
the	NULL
II-4	NULL
and	NULL
II-2	NULL
promoters	NULL
are	NULL
bound	NULL
by	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

The	NULL
most	NULL
prominent	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
protein	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
I1-4	NULL
promoter	NULL
is	NULL
box	NULL
II	NULL
,	NULL
but	NULL
several	NULL
other	NULL
AT	NULL
rich	NULL
promoter	NULL
sites	NULL
,	NULL
such	NULL
as	NULL
the	NULL
Pu-boxes	NULL
B	NULL
and	NULL
C	NULL
also	NULL
interact	NULL
with	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

HMG	NULL
proteins	NULL
,	NULL
which	NULL
constitute	NULL
up	NULL
to	NULL
5	NULL
%	NULL
of	NULL
nuclear	NULL
chromatin	NULL
,	NULL
have	NULL
been	NULL
described	NULL
as	NULL
regulators	NULL
of	NULL
DNA	NULL
replication	NULL
(	NULL
44	NULL
)	NULL
and	NULL
gene	NULL
transcription	NULL
.	NULL

For	NULL
the	NULL
virus-inducible	NULL
promoter	NULL
of	NULL
the	NULL
IFN-3	NULL
gene	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
that	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
stimulates	NULL
the	NULL
binding	NULL
of	NULL
NF-xB	NULL
to	NULL
a	NULL
non-canonical	NULL
NF-xB	NULL
site	NULL
,	NULL
and	NULL
its	NULL
synthesis	NULL
appeared	NULL
to	NULL
be	NULL
crucial	NULL
for	NULL
the	NULL
virus-mediated	NULL
promoter	NULL
induction	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
to	NULL
AT	NULL
rich	NULL
stretches	NULL
of	NULL
rRNA	NULL
and	NULL
lymphotoxin	NULL
promoters	NULL
(	NULL
46	NULL
,	NULL
47	NULL
)	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
stimulation	NULL
of	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

In	NULL
our	NULL
experiments	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
exerted	NULL
a	NULL
pronounced	NULL
suppressive	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

One	NULL
target	NULL
of	NULL
this	NULL
suppression	NULL
is	NULL
box	NULL
II	NULL
but	NULL
other	NULL
sequence	NULL
elements	NULL
might	NULL
also	NULL
be	NULL
involved	NULL
.	NULL

Experiments	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
elucidate	NULL
in	NULL
more	NULL
detail	NULL
how	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
suppresses	NULL
the	NULL
II-4	NULL
promoter	NULL
activity	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Apart	NULL
from	NULL
the	NULL
lack	NULL
of	NULL
a	NULL
high	NULL
affinity	NULL
Oct	NULL
site	NULL
,	NULL
the	NULL
I-4	NULL
promoter	NULL
also	NULL
lacks	NULL
NF-xB	NULL
and	NULL
AP-1	NULL
(	NULL
TRE	NULL
)	NULL
sites	NULL
which	NULL
are	NULL
part	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
.	NULL

The	NULL
TREp	NULL
(	NULL
proximal	NULL
TRE	NULL
)	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
has	NULL
been	NULL
described	NULL
to	NULL
be	NULL
an	NULL
important	NULL
AP-1	NULL
binding	NULL
site	NULL
through	NULL
which	NULL
the	NULL
effect	NULL
of	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
is	NULL
mediated	NULL
in	NULL
untransformed	NULL
T	NULL
cells	NULL
(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mutation	NULL
of	NULL
TREp	NULL
to	NULL
a	NULL
defective	NULL
AP-1	NULL
binding	NULL
site	NULL
had	NULL
only	NULL
a	NULL
minor	NULL
effect	NULL
on	NULL
the	NULL
II-2	NULL
promoter	NULL
activity	NULL
in	NULL
T	NULL
lymphoma	NULL
(	NULL
El4	NULL
)	NULL
cells	NULL
,	NULL
while	NULL
that	NULL
of	NULL
the	NULL
xB-like	NULL
TCEd	NULL
element	NULL
abolished	NULL
promoter	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
5703	NULL
activity	NULL
(	NULL
26	NULL
and	NULL
unpubl	NULL
.	NULL

results	NULL
)	NULL
.	NULL

In	NULL
further	NULL
experiments	NULL
,	NULL
the	NULL
TCEd	NULL
appeared	NULL
to	NULL
be	NULL
the	NULL
only	NULL
II-2	NULL
proto-enhancer	NULL
element	NULL
the	NULL
induction	NULL
of	NULL
which	NULL
was	NULL
impaired	NULL
by	NULL
agonists	NULL
of	NULL
PKA	NULL
(	NULL
T.Grieshammer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpubl	NULL
.	NULL

results	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
Il-4	NULL
promoter	NULL
is	NULL
not	NULL
suppressed	NULL
by	NULL
increased	NULL
PKA	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
and	NULL
high	NULL
cAMP	NULL
levels	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
Th2	NULL
cell	NULL
clones	NULL
(	NULL
5	NULL
)	NULL
,	NULL
one	NULL
may	NULL
speculate	NULL
that	NULL
the	NULL
negative	NULL
effect	NULL
of	NULL
PKA	NULL
on	NULL
1-2	NULL
gene	NULL
activity	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
for	NULL
a	NULL
review	NULL
see	NULL
50	NULL
)	NULL
is	NULL
mediated	NULL
through	NULL
the	NULL
xB-like	NULL
TCEd	NULL
of	NULL
the	NULL
II-2	NULL
promoter	NULL
.	NULL

In	NULL
EMSA	NULL
experiments	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
different	NULL
Thl1	NULL
(	NULL
LNC-2	NULL
:	NULL
51	NULL
;	NULL
â¬57.4	NULL
:	NULL
;	NULL
52	NULL
)	NULL
and	NULL
Th2	NULL
cell	NULL
lines	NULL
(	NULL
D10	NULL
:	NULL
53	NULL
;	NULL
L1/1	NULL
:	NULL
54	NULL
)	NULL
we	NULL
did	NULL
not	NULL
observe	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
patterns	NULL
of	NULL
transacting	NULL
factors	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
induced	NULL
by	NULL
TPA/ionomycin	NULL
.	NULL

However	NULL
,	NULL
differences	NULL
were	NULL
observed	NULL
upon	NULL
other	NULL
treatments	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

This	NULL
might	NULL
imply	NULL
that	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
differ	NULL
in	NULL
the	NULL
existence	NULL
of	NULL
various	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
since	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
appear	NULL
to	NULL
differentiate	NULL
from	NULL
common	NULL
progenitor	NULL
cells	NULL
in	NULL
which	NULL
both	NULL
lymphokines	NULL
are	NULL
synthesized	NULL
(	NULL
see	NULL
11	NULL
)	NULL
,	NULL
one	NULL
may	NULL
conclude	NULL
that	NULL
the	NULL
(	NULL
promoter	NULL
)	NULL
activity	NULL
of	NULL
genes	NULL
is	NULL
switched	NULL
off	NULL
in	NULL
the	NULL
Th	NULL
cell	NULL
type	NULL
where	NULL
they	NULL
are	NULL
not	NULL
synthesized	NULL
.	NULL

For	NULL
the	NULL
II-2	NULL
promoter	NULL
,	NULL
two	NULL
sites	NULL
have	NULL
been	NULL
implicated	NULL
to	NULL
bind	NULL
negatively	NULL
acting	NULL
factors	NULL
(	NULL
55	NULL
,	NULL
56	NULL
)	NULL
but	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
shown	NULL
whether	NULL
these	NULL
factors	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
neither	NULL
of	NULL
the	NULL
negatively	NULL
acting	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
further	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
I1-4	NULL
promoter	NULL
(	NULL
between	NULL
the	NULL
positions	NULL
-270	NULL
and	NULL
-307	NULL
:	NULL
see	NULL
Fig	NULL
.	NULL

1B	NULL
and	NULL
14	NULL
)	NULL
have	NULL
been	NULL
studied	NULL
in	NULL
Th1	NULL
cells	NULL
,	NULL
nor	NULL
the	NULL
putative	NULL
repressor	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
far	NULL
upstream	NULL
promoter	NULL
region	NULL
in	NULL
front	NULL
of	NULL
position	NULL
-797	NULL
.	NULL

Thus	NULL
,	NULL
more	NULL
experiments	NULL
,	NULL
in	NULL
particular	NULL
in	NULL
vivo	NULL
assays	NULL
,	NULL
are	NULL
necessary	NULL
to	NULL
elucidate	NULL
which	NULL
transcription	NULL
factors	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
divergent	NULL
transcription	NULL
of	NULL
lymphokine	NULL
genes	NULL
in	NULL
Th	NULL
cells	NULL
.	NULL

When	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
was	NULL
completed	NULL
two	NULL
reports	NULL
appeared	NULL
on	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
genes	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Both	NULL
communications	NULL
support	NULL
our	NULL
findings	NULL
on	NULL
the	NULL
multiplicity	NULL
of	NULL
I-4	NULL
promoter	NULL
elements	NULL
.	NULL

Szabo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
59	NULL
)	NULL
described	NULL
five	NULL
NFAT/purine	NULL
box	NULL
like	NULL
elements	NULL
as	NULL
part	NULL
of	NULL
the	NULL
murine	NULL
II-4	NULL
promoter	NULL
.	NULL

Four	NULL
of	NULL
them	NULL
correspond	NULL
to	NULL
our	NULL
Pu-boxes	NULL
A	NULL
-D	NULL
,	NULL
whereas	NULL
the	NULL
fifth	NULL
located	NULL
around	NULL
position	NULL
-175	NULL
might	NULL
be	NULL
inactive	NULL
in	NULL
the	NULL
El4	NULL
cell	NULL
line	NULL
we	NULL
used	NULL
since	NULL
we	NULL
never	NULL
detected	NULL
any	NULL
footprint	NULL
at	NULL
this	NULL
site	NULL
.	NULL

In	NULL
additon	NULL
,	NULL
these	NULL
authors	NULL
identified	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
cloned	NULL
nuclear	NULL
factor	NULL
NF-Y	NULL
(	NULL
59	NULL
)	NULL
to	NULL
box	NULL
I	NULL
of	NULL
the	NULL
II-4	NULL
promoter	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
We	NULL
are	NULL
very	NULL
much	NULL
indebted	NULL
to	NULL
Elke	NULL
Leibold	NULL
and	NULL
Hona	NULL
Pietrowski	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
and	NULL
to	NULL
Cornelia	NULL
Escher	NULL
,	NULL
T.Grieshammer	NULL
and	NULL
Isolde	NULL
Pfeuffer	NULL
for	NULL
art	NULL
work	NULL
.	NULL

For	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
we	NULL
wish	NULL
to	NULL
thank	NULL
Drs	NULL
.	NULL

L.	NULL
Dunster	NULL
and	NULL
Anneliese	NULL
Schimpl	NULL
.	NULL

For	NULL
many	NULL
helpful	NULL
discussions	NULL
and	NULL
gifts	NULL
of	NULL
reagents	NULL
we	NULL
wish	NULL
to	NULL
thank	NULL
Drs	NULL
.	NULL

P.Krammer	NULL
(	NULL
Heidelberg	NULL
)	NULL
,	NULL
Min	NULL
Li-Weber	NULL
(	NULL
Heidelberg	NULL
)	NULL
,	NULL
M.Lohoff	NULL
(	NULL
Erlangen	NULL
)	NULL
and	NULL
P.Matthias	NULL
(	NULL
Basel	NULL
)	NULL
.	NULL

For	NULL
gifts	NULL
of	NULL
materials	NULL
we	NULL
are	NULL
indebted	NULL
to	NULL
Drs	NULL
.	NULL

Naoko	NULL
Arai	NULL
(	NULL
Palo	NULL
Alto	NULL
)	NULL
,	NULL
Melissa	NULL
Brown	NULL
(	NULL
Portland	NULL
)	NULL
,	NULL
C.Carliberg	NULL
(	NULL
Geneva	NULL
)	NULL
,	NULL
F.	NULL
Mercurio	NULL
(	NULL
San	NULL
Diego	NULL
)	NULL
and	NULL
P.	NULL
Stein	NULL
(	NULL
Karlsruhe	NULL
)	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungs-gemeinschaft	NULL
,	NULL
SFB	NULL
165	NULL
(	NULL
Wiirzburg	NULL
)	NULL
,	NULL
the	NULL
Bayerische	NULL
Forschungs-stiftung	NULL
,	NULL
the	NULL
Fonds	NULL
der	NULL
Chemischen	NULL
Industrie	NULL
(	NULL
to	NULL
E.S	NULL
.	NULL
)	NULL

and	NULL
the	NULL
EC	NULL
(	NULL
Bridge	NULL
,	NULL
to	NULL
F.G.	NULL
)	NULL
.	NULL

5704	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1993	NULL
,	NULL
Vol	NULL
.	NULL

21	NULL
,	NULL
No	NULL
.	NULL

24	NULL
REFERENCES	NULL
G	NULL
ba	NULL
On	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38.	NULL
.	NULL

Mosmann	NULL
,	NULL
T.R	NULL
.	NULL

and	NULL
Moore	NULL
,	NULL
K.W	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
12	NULL
,	NULL
A49-A53	NULL
.	NULL

.	NULL

Sher	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Coffman	NULL
,	NULL
R.L	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Annu.Rev.Immunol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
385-409.	NULL
.	NULL

Munoz	NULL
,	NULL
E.	NULL
,	NULL
Zubiaga	NULL
,	NULL
A.M.	NULL
,	NULL
Merrow	NULL
,	NULL
M.	NULL
,	NULL
Sauter	NULL
,	NULL
N.P	NULL
.	NULL

and	NULL
Huber	NULL
,	NULL
B.T	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.Exp.Med	NULL
.	NULL

172	NULL
,	NULL
95-103.	NULL
.	NULL

Novak	NULL
,	NULL
T.J	NULL
.	NULL

and	NULL
Rothenberg	NULL
,	NULL
E.V	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc.Natl.Acad.Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
9353-9357.	NULL
.	NULL

Betz	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Fox	NULL
,	NULL
B.S	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
108-113.	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
Felli	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
Farina	NULL
,	NULL
A.R	NULL
.	NULL

,	NULL
Martinotti	NULL
,	NULL
S.	NULL
,	NULL
Maroder	NULL
,	NULL
M.	NULL
,	NULL
Screpanti,1	NULL
.	NULL

,	NULL
Meco	NULL
,	NULL
D.	NULL
,	NULL
Petrangeli	NULL
,	NULL
E.	NULL
,	NULL
Frati	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Gulino	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
637-646.	NULL
.	NULL

Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Mattila	NULL
,	NULL
P.S	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.Exp.Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
1235-1245.	NULL
.	NULL

Daynes	NULL
,	NULL
R.A	NULL
.	NULL

and	NULL
Araneo	NULL
,	NULL
B.A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Eur.J.Immunol	NULL
.	NULL

,	NULL
19	NULL
,	NULL
2319-2325.	NULL
.	NULL

Otsuka	NULL
,	NULL
T.	NULL
,	NULL
Vallaret	NULL
,	NULL
D.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Takebe	NULL
,	NULL
Y.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
Arai	NULL
,	NULL
N.	NULL
and	NULL
Arai	NULL
,	NULL
N	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
15	NULL
,	NULL
333-344.	NULL
.	NULL

Arai	NULL
,	NULL
N.	NULL
,	NULL
Nomura	NULL
,	NULL
D.	NULL
,	NULL
Villaret	NULL
,	NULL
D.	NULL
,	NULL
DeWaal	NULL
Malefjjt.R	NULL
.	NULL

,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Minoshima	NULL
,	NULL
S.	NULL
,	NULL
Fukuyama	NULL
,	NULL
R.	NULL
,	NULL
Maekawa	NULL
,	NULL
M.	NULL
,	NULL
Kudoh	NULL
,	NULL
J.	NULL
,	NULL
Shimizu	NULL
,	NULL
N.	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Takebe	NULL
,	NULL
Y	NULL
.	NULL

and	NULL
Arai	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
142	NULL
,	NULL
274-282.	NULL
.	NULL

Arai	NULL
,	NULL
N.	NULL
,	NULL
Naito	NULL
,	NULL
Y.	NULL
,	NULL
Watanabe	NULL
,	NULL
M.	NULL
,	NULL
Masuda	NULL
,	NULL
E.S	NULL
.	NULL

,	NULL
Yamaguchi-Iwai	NULL
,	NULL
Y.	NULL
,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Heike	NULL
,	NULL
T.	NULL
,	NULL
Matsuda	NULL
,	NULL
L	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Koyano-Nakagawa	NULL
,	NULL
N.	NULL
,	NULL
Lee	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
Muramatsu	NULL
,	NULL
M.	NULL
,	NULL
Yokota	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Arai	NULL
,	NULL
K.I	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Pharmac.Ther	NULL
.	NULL

,	NULL
55	NULL
,	NULL
303-318.	NULL
.	NULL

Henkel	NULL
,	NULL
G.	NULL
,	NULL
Weiss	NULL
,	NULL
D.L	NULL
.	NULL

,	NULL
McCoy	NULL
,	NULL
R.	NULL
,	NULL
Delouchery	NULL
,	NULL
T.	NULL
,	NULL
Tara	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Brown	NULL
,	NULL
M.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.Immunol	NULL
.	NULL

,	NULL
149	NULL
,	NULL
3239-3246.	NULL
.	NULL

Abe	NULL
,	NULL
E.	NULL
,	NULL
de	NULL
Waal	NULL
Malefyt	NULL
,	NULL
R.	NULL
,	NULL
Matsuda	NULL
,	NULL
L.	NULL
,	NULL
Arai	NULL
,	NULL
K.-I	NULL
.	NULL

and	NULL
Arai	NULL
,	NULL
N	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
2864-2868.	NULL
.	NULL

Li-Weber	NULL
,	NULL
M.	NULL
,	NULL
Eder	NULL
,	NULL
A.	NULL
,	NULL
Krafft-Czepa	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Krammer	NULL
,	NULL
P.H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
1913-1918.	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmis	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
465-473.	NULL
.	NULL

Hunt	NULL
,	NULL
S.V	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
In	NULL
:	NULL
Lymphocytes	NULL
,	NULL
a	NULL
practical	NULL
approach	NULL
(	NULL
Klaus,0.0.B	NULL
.	NULL

,	NULL
Ed	NULL
.	NULL
)	NULL

,	NULL
pp	NULL
.	NULL

1-34	NULL
.	NULL

IRL	NULL
Press	NULL
,	NULL
Oxford	NULL
,	NULL
Washingthon	NULL
,	NULL
D.C	NULL
.	NULL

.	NULL

Luckow	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Schiitz	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
15	NULL
,	NULL
5490.	NULL
.	NULL

Higuchi	NULL
,	NULL
R.	NULL
,	NULL
Krummel	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Saiki	NULL
,	NULL
R.K	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
16	NULL
,	NULL
7351-67.	NULL
.	NULL

Johnson	NULL
,	NULL
K.R	NULL
.	NULL

,	NULL
Lehn	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Elton	NULL
,	NULL
T.S	NULL
.	NULL

,	NULL
Barr	NULL
,	NULL
P.J	NULL
.	NULL

and	NULL
Reeves	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.Biol.Chem	NULL
.	NULL

,	NULL
263	NULL
,	NULL
18338-18342.	NULL
.	NULL

Green	NULL
,	NULL
S.	NULL
,	NULL
Issemann	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Sheer	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
16	NULL
,	NULL
369	NULL
.	NULL

.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Miiller	NULL
,	NULL
M.M	NULL
.	NULL

and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
17	NULL
,	NULL
6419.	NULL
.	NULL

Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Pictrowski	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
19	NULL
,	NULL
61-67.	NULL
.	NULL

Winoto	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
729-733.	NULL
.	NULL

Leiden	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Immunol.Today	NULL
,	NULL
13	NULL
,	NULL
22-30.	NULL
.	NULL

Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
Schorr	NULL
,	NULL
E.	NULL
,	NULL
Siebelt	NULL
,	NULL
F.	NULL
,	NULL
Wirth	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Serfling.E	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol.Cell.Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
1155-1162	NULL
.	NULL

Briegel	NULL
,	NULL
K.	NULL
,	NULL
Hentsch	NULL
,	NULL
B.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
19	NULL
,	NULL
5929-5936	NULL
.	NULL

Smith	NULL
,	NULL
D.B	NULL
.	NULL

and	NULL
Johnson	NULL
,	NULL
K.S	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Gene	NULL
,	NULL
67	NULL
,	NULL
31-40	NULL
.	NULL

Dignam	NULL
,	NULL
J.0	NULL
.	NULL

,	NULL
Lebowitz	NULL
,	NULL
R.M	NULL
.	NULL

and	NULL
Roeder	NULL
,	NULL
R.G	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
1475-1489	NULL
.	NULL

Dallman	NULL
,	NULL
M.J.	NULL
,	NULL
Montgomery	NULL
,	NULL
R.A.	NULL
,	NULL
Larsen	NULL
,	NULL
C.P	NULL
.	NULL

,	NULL
Wanders	NULL
,	NULL
A.	NULL
and	NULL
Wells	NULL
,	NULL
F	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Immunol	NULL
.	NULL

Reviews	NULL
,	NULL
119	NULL
,	NULL
163-178	NULL
.	NULL

Novak	NULL
,	NULL
T	NULL
.J	NULL
.	NULL

,	NULL
Whilte	NULL
,	NULL
P	NULL
.	NULL

M.	NULL
and	NULL
Rothenberg	NULL
,	NULL
E.V	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nucl	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
,	NULL
4523-4533	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
HergenrÃ©other	NULL
,	NULL
M.	NULL
,	NULL
Sobotta	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2529-2536	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.G	NULL
.	NULL

,	NULL
Valge-Archer	NULL
,	NULL
V.E	NULL
.	NULL

and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
Mao	NULL
,	NULL
X.	NULL
,	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
Lindsten	NULL
,	NULL
T	NULL
.	NULL

,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Kovary	NULL
,	NULL
K.	NULL
,	NULL
Leiden	NULL
,	NULL
J	NULL
.	NULL

M.	NULL
and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
1911-1919	NULL
.	NULL

Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Uliman	NULL
,	NULL
K.S	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
,	NULL
2917-2923	NULL
.	NULL

Catron	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Her	NULL
,	NULL
N	NULL
.	NULL

and	NULL
Abate	NULL
,	NULL
C	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol.Cell	NULL
Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
2354-2365	NULL
.	NULL

Solomon	NULL
,	NULL
M.J.	NULL
,	NULL
Strauss	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Varshavsky	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
1276-1280	NULL
.	NULL

Shaw	NULL
,	NULL
J.P.	NULL
,	NULL
Utz	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Toole	NULL
,	NULL
.J.J	NULL
.	NULL

,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202-205	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Verweij	NULL
,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Higgins	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Lacy.E	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

and	NULL
39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45.	NULL
.	NULL

Yang-Yen	NULL
,	NULL
H.F	NULL
.	NULL

and	NULL
Rothblum	NULL
,	NULL
L.I	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Mol.Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
3406-3414	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59.	NULL
.	NULL

Liu	NULL
,	NULL
)	NULL
.	NULL

,	NULL
Flanagan	NULL
,	NULL
W.F	NULL
.	NULL

,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.J	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
,	NULL
352	NULL
,	NULL
803-807	NULL
.	NULL

Farmer	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Lane	NULL
,	NULL
W.S	NULL
.	NULL

,	NULL
Friedman.J	NULL
.	NULL

,	NULL
Schreiber	NULL
,	NULL
S.L	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
,	NULL
66	NULL
,	NULL
807-815	NULL
.	NULL

O'Keefe	NULL
,	NULL
$	NULL
.J	NULL
.	NULL

,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
Tocci	NULL
,	NULL
M.J	NULL
.	NULL

and	NULL
O'Neill	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
357	NULL
,	NULL
692-694	NULL
.	NULL

Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
357	NULL
,	NULL
695-697	NULL
.	NULL

Cockerill	NULL
,	NULL
P.N	NULL
.	NULL

,	NULL
Shannon	NULL
,	NULL
M.F	NULL
.	NULL

,	NULL
Bert	NULL
,	NULL
Ryan	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Vadas	NULL
,	NULL
M.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad.Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
2466-2470	NULL
.	NULL

Weissman.I	NULL
.	NULL

and	NULL
.	NULL

Wegner	NULL
,	NULL
M.	NULL
,	NULL
Zastrow	NULL
,	NULL
G.	NULL
,	NULL
Klavinius	NULL
,	NULL
A.	NULL
,	NULL
Schwender	NULL
,	NULL
$	NULL
S.	NULL
,	NULL
Miiller	NULL
,	NULL
F.	NULL
,	NULL
Luksza	NULL
,	NULL
H..	NULL
Hoppe	NULL
,	NULL
J.	NULL
,	NULL
Wienberg.J	NULL
.	NULL

and	NULL
Grummt.F	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nucl.Acids	NULL
Res..	NULL
17	NULL
,	NULL
9909-9932	NULL
.	NULL

Thanos	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Maniatis	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
,	NULL
71	NULL
,	NULL
777-789	NULL
.	NULL

Fashena	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Reeves	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Ruddle	NULL
,	NULL
N.H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol.Cell.Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
894-903	NULL
.	NULL

Kang	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.H	NULL
.	NULL

and	NULL
Lenardo	NULL
,	NULL
M.J.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
,	NULL
257	NULL
,	NULL
1134-1138	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.E	NULL
.	NULL

,	NULL
Sinskey	NULL
,	NULL
A.J	NULL
.	NULL

and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
853-862	NULL
.	NULL

Kammer	NULL
,	NULL
G.M	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
9	NULL
,	NULL
222-229	NULL
.	NULL

Schmitt	NULL
,	NULL
E.	NULL
,	NULL
van	NULL
Brandwijk	NULL
,	NULL
R.	NULL
,	NULL
van	NULL
Snick	NULL
,	NULL
J..	NULL
Siebold	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Riide	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Eur.J.Immunol	NULL
.	NULL

19	NULL
,	NULL
2167-2170	NULL
.	NULL

Lohoff	NULL
,	NULL
M.	NULL
,	NULL
Schmitt	NULL
,	NULL
E.	NULL
,	NULL
Reske-Kunz	NULL
,	NULL
A.B	NULL
.	NULL

and	NULL
Rollinghoff	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Eur.J.Immunol	NULL
.	NULL

,	NULL
20	NULL
,	NULL
653-658	NULL
.	NULL

Kaye	NULL
,	NULL
J.	NULL
,	NULL
Porcelli	NULL
,	NULL
S.	NULL
,	NULL
Tite	NULL
,	NULL
J.	NULL
,	NULL
Jones	NULL
,	NULL
B.	NULL
and	NULL
Janeway	NULL
,	NULL
C	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
158	NULL
,	NULL
836-856.	NULL
.	NULL

Lohoff	NULL
,	NULL
M.	NULL
,	NULL
Sommer	NULL
,	NULL
F.	NULL
,	NULL
Solbach	NULL
,	NULL
W.	NULL
and	NULL
Roillinghoff	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Immunobiol	NULL
.	NULL

,	NULL
179	NULL
,	NULL
412-421	NULL
.	NULL

Mouzaki	NULL
,	NULL
A.	NULL
,	NULL
Weil	NULL
,	NULL
R.	NULL
,	NULL
Muster	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Rungger	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
1399-1406	NULL
.	NULL

Williams	NULL
,	NULL
T.M	NULL
.	NULL

,	NULL
Moolten	NULL
,	NULL
D.	NULL
,	NULL
Burlein	NULL
,	NULL
J.	NULL
,	NULL
Romano	NULL
,	NULL
J.	NULL
,	NULL
Bhaerman	NULL
,	NULL
R.	NULL
,	NULL
Godillot	NULL
,	NULL
A.	NULL
,	NULL
Mellon	NULL
,	NULL
M.	NULL
,	NULL
Rauscher	NULL
HL	NULL
,	NULL
F.J	NULL
.	NULL

and	NULL
Kant	NULL
,	NULL
J.A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
,	NULL
254	NULL
,	NULL
1791-1794	NULL
.	NULL

Todd	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Grusby	NULL
,	NULL
M.J.	NULL
,	NULL
Lederer	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
Lichtman	NULL
,	NULL
A.H	NULL
.	NULL

and	NULL
Glimscher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.Exp.Med	NULL
.	NULL

177	NULL
,	NULL
1663-1674	NULL
.	NULL

Szabo	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Gold	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Murphy	NULL
,	NULL
T.L	NULL
.	NULL

and	NULL
Murphy.K	NULL
.	NULL

M.	NULL
(	NULL
1993	NULL
)	NULL
Mol.Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
4793-4805	NULL
.	NULL

Benoist	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Mathis	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Annu.Rev.Immunol	NULL
.	NULL

13	NULL
,	NULL
681-715	NULL
.	NULL

